## Professional development: Teaching, learning and assessments: key principles

**Aims:** To describe the key concepts in teaching, learning and assessment in the medical education context; to identify the different adult learning theories i.e. Andragogy, heutagogy etc.; to recall the teacher’s toolkit and apply the relevant tools for each teaching intervention (i.e. small and large group learning, teaching in the clinical context, peer learning, simulation); to identify when to use formative vs summative assessment methods.

**Tag(s):** Clinical

**Target audience:** Thoracic surgeon, Paediatrician, Respiratory critical care physician, Adult pulmonologist/Clinician, General practitioner, Physician in Pulmonary Training

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction and summary of online module</td>
<td>Stefano Aliberti (Milano (MI), Italy)</td>
</tr>
<tr>
<td>Adult learning theory: practical session</td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>Teaching and learning</td>
<td>Annie Noble (Bristol, United Kingdom)</td>
</tr>
<tr>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>Formative and summative assessment</td>
<td>Robert Primhak (Sheffield (South Yorkshire), United Kingdom)</td>
</tr>
</tbody>
</table>

## Professional development: Medical writing

**Aims:** To describe the basics of medical writing to an audience of ERS members at various levels in their professional careers.

**Tag(s):** Translational

**Target audience:** Clinical researcher, Physician in Pulmonary Training, General practitioner, Scientist (basic, translational), Medical Student

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome</td>
<td>Gilbert Massard (Esch Sur Alzette, Luxembourg), Speaker to be confirmed</td>
</tr>
<tr>
<td>Introduction. Why should we publish?</td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>Learn from errors exercise: group exercise</td>
<td>Gilbert Massard (Esch Sur Alzette, Luxembourg), Speaker to be confirmed</td>
</tr>
<tr>
<td>Different types of articles</td>
<td>Gilbert Massard (Esch Sur Alzette, Luxembourg)</td>
</tr>
<tr>
<td>Cycle of a manuscript</td>
<td>Gilbert Massard (Esch Sur Alzette, Luxembourg)</td>
</tr>
<tr>
<td>Feedback and evaluation</td>
<td>Gilbert Massard (Esch Sur Alzette, Luxembourg), Speaker to be confirmed</td>
</tr>
</tbody>
</table>

## Professional development: Leading and managing change

**Aims:** To describe the causes of resistance to change and strategies to overcome this resistance; to describe steps to use in planned changes; and to effectively communicate with and motivate staff members throughout the change process.

**Target audience:** Clinical researcher, Respiratory critical care physician, General practitioner, Medical Technical Assistant, Nurse, Paediatrician, Patient, Pathologist, Physiologist, Respiratory physiotherapist, Radiologist, Scientist (basic, translational), Medical Student, Thoracic oncologist, Thoracic surgeon, Adult pulmonologist/Clinician, Physician in Pulmonary Training, Respiratory therapist

<table>
<thead>
<tr>
<th>Topic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction: overview of leading and managing change</td>
<td></td>
</tr>
</tbody>
</table>
Why change efforts might fail: what research tells us
Speaker to be confirmed

Personal responses to change
Speaker to be confirmed

The planned change process: steps and guidelines
Speaker to be confirmed

The leader as a role model
Speaker to be confirmed

Action planning: how to apply what has been learned
Speaker to be confirmed

Questions and answers
Speaker to be confirmed

Pre-congress content

Professional development: How to deal with difficult people

Aims: To describe methods enabling caregivers to deal with challenging situations; to enhance effective communication skills; and to identify difficult personality types and describe specific strategies for dealing with them.

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Respiratory critical care physician, General practitioner, Medical Technical Assistant, Nurse, Paediatrician, Patient, Pathologist, Physiologist, Respiratory physiotherapist, Radiologist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon, Physician in Pulmonary Training, Medical Student, Respiratory therapist

Introduction: What makes a situation challenging?
Speaker to be confirmed

How to implement a communication approach: a step-by-step guide
Speaker to be confirmed

Applying the communication approach to common difficult situations: case discussion in small groups
Speaker to be confirmed

How to use a coping technique when communication fails
Speaker to be confirmed

Summary
Speaker to be confirmed

Questions and answers
Speaker to be confirmed

Pre-congress content

Professional development: Teamability: becoming an effective team leader and member

Aims: To describe the characteristics of effective and ineffective teams, team leaders and team members; to describe various styles of team interaction and the integration of these styles; to evaluate skills to use in building relationships, managing differences and building trust and collaboration; and to describe methods to collaboratively lead and participate in healthcare teams.

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory critical care physician, Respiratory physiotherapist, Respiratory therapist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon

Introduction: Overview of why teamwork is essential to the delivery of good healthcare

What makes a healthcare team effective?
Speaker to be confirmed

Stages of team development: how to lead and participate effectively through emotions, behaviours and tasks.
Speaker to be confirmed

Action planning: how to apply what has been learned
Speaker to be confirmed
Hot topics: The changing and challenging landscape of the global tobacco epidemic: from vaping to cannabis?

**Aims**: To raise awareness among the respiratory health care community about the tobacco epidemic changing landscape and nicotine additive products evolution; to inform respiratory healthcare providers about cannabis health effects, from medicinal use to health hazards (focusing on lung health); to update the latest scientific findings and inform the respiratory health care community on the health effects of novel and emergent cannabis, tobacco and nicotine products; to raise awareness for the need to involve respiratory health care providers and researchers, the patients and the public on the cannabis legalization debate.

**Disease(s)**: Airway diseases, Paediatric respiratory diseases, Respiratory infections

**Tag(s)**: Clinical

**Target audience**: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Respiratory physiotherapist, Thoracic oncologist, Thoracic surgeon, Respiratory therapist, Journalist

00:00  
**Now it is not only about cigarettes: dual, triple, multiuse of nicotine and cannabis products. What to expect (focus on lung health)**
Charlotta Pisinger (Frederiksberg, Denmark)

00:00  
**Paediatric concerns due to expanded cannabis use: from prenatal to postnatal cannabis exposure; from early lung and immune system development to the immature brain of children and teens**
Speaker to be confirmed

00:00  
**What we know and what we do not know about cannabis health effects: a concern for lung health?**
Speaker to be confirmed

00:35  
**Behind the scenes. The public health concerns of marijuana legalization; from production to marketing and recreational use**
Speaker to be confirmed

Year in review: Clinical Year in review

**Exercise capacity and physical activity in paediatric respiratory diseases**

**Aims**: To evaluate the pathophysiology of exercise intolerance in children and adolescents with bronchopulmonary dysplasia (BPD), asthma, congenital heart disease (CHD), and cystic fibrosis (CF); to provide updates on recent advances in paediatric exercise intervention research; to describe strategies to promote physical activity in paediatric respiratory disease patients; to describe diagnostic approaches to assess exercise capacity in paediatric respiratory diseases patients; and to compare the safety and efficacy of exercise regimes among children with respiratory disease.

**Disease(s)**: Airway diseases, Paediatric respiratory diseases, Respiratory infections

**Tag(s)**: Clinical

**Target audience**: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Paediatrician, Pathologist, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

00:00  
**Diverging effects of premature birth and bronchopulmonary dysplasia on exercise capacity and physical activity: a case control study**
Speaker to be confirmed

00:25  
**Physical activity and asthma development in childhood: prospective birth cohort study**
Speaker to be confirmed

00:50  
**Impaired pulmonary function and its association with clinical outcomes, exercise capacity and quality of life in children with congenital heart disease**
Speaker to be confirmed

01:15  
**Test-retest reliability, minimal detectable change and minimal clinically important differences in the modified shuttle walk test in children and adolescents with cystic fibrosis**
Speaker to be confirmed

Year in review: Scientific year in review

**Mechanisms regulating lung diseases across the lifespan**
Aims: To describe recent scientific advances in preterm, infant, childhood and adolescent/adult lung health and in two major lung diseases in adults and the elderly; to describe the impact of preterm and childhood events on lifelong lung health; to explain how diet, metabolism, genetics and the epigenome modulate asthma severity in childhood; to determine the contributions of lifestyle and environmental factors to the evolution of COPD; and to identify similarities in the mechanisms underlying lung cancer and idiopathic pulmonary fibrosis.

**Disease(s):** Airway diseases, Interstitial lung diseases, Paediatric respiratory diseases

**Tag(s):** Translational

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Scientist (basic, translational), Thoracic oncologist, Journalist

---

**Pre-congress content Session 00:00 - 23:59**

**Year in review: Paediatric year in review**

**Aims:** To describe advances in paediatric respiratory medicine occurring over the past year.

**Disease(s):** Paediatric respiratory diseases

**Tag(s):** Clinical

**Target audience:** Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational)

---

**Expert view: Bronchoscopy interventions in ventilated patients**

Do invasive pulmonary interventions alter treatment of ventilated patients in the intensive care unit with consolidations?

**Aims:** To describe the specific risks associated with bronchoscopic interventions in ventilated critically ill patients; to assess methods available to obtain lung tissue samples from ventilated critically ill patients; and to determine categories of critically ill patients who may benefit from bronchoscopy guided lung tissue biopsy.

This session is applicable to training, including training of radiologists, respiratory critical care physicians, journalists, basic and applied scientists, and thoracic surgeons.

**Disease(s):** Interstitial lung diseases, Respiratory critical care, Respiratory infections

**Method(s):** Endoscopy and interventional pulmonology, General respiratory patient care, Respiratory intensive care

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Paediatrician, Pathologist, Physician in Pulmonary Training, Radiologist, Respiratory critical care physician, Journalist, Scientist (basic, translational), Thoracic surgeon

---

**Expert view: Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis**
Aims: To present state of the art decision algorithms, based on serologic testing, the pathogenesis of lung inflammation and the development of fibrosis, in the diagnosis (laboratory, radiology, pathology) and management of patients with chronic fibrotic hypersensitivity pneumonitis; to describe subtle radiological findings that differentiate this disease from other interstitial lung diseases, such as usual interstitial pneumonia; to evaluate the pathological diagnosis of chronic fibrotic hypersensitivity pneumonitis; and to assess the efficacy of anti-fibrotic and immunosuppressive agents.

Disease(s): Interstitial lung diseases
Method(s): Cell and molecular biology  General respiratory patient care  Imaging
Tag(s): Translational
Target audience: Clinical researcher, General practitioner, Pathologist, Radiologist, Respiratory critical care physician, Scientist (basic, translational)

00:00  Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis
Wim A Wuyts (Rotselaar, Belgium)

Pre-congress content  Session  00:00 - 23:59
Expert view: Tips and pitfalls of cardiopulmonary exercise testing

Aims: To describe the physiological basis of exercise testing and its clinical application to lung diseases; to describe the indications and protocols used in clinical settings (e.g., incremental, constant work-rate); to evaluate the utility of exercise testing in pharmacological and non-pharmacological interventions; and to describe the importance of exercise testing in patient prognosis.

Disease(s): Sleep and breathing disorders
Method(s): Physiology
Tag(s): Clinical
Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist

00:00  Tips and pitfalls of cardiopulmonary exercise testing
Paolo Palange (Rome, Italy)

Pre-congress content  Session  00:00 - 23:59
Expert view: Successfully managing adolescent and young adult patients with asthma

Aims: To describe the challenges faced by adolescents and young adults with asthma and their status as at risk patients; and to evaluate methods enabling adolescents and young adults to better self-manage their asthma.

Disease(s): Airway diseases  Paediatric respiratory diseases
Method(s): General respiratory patient care  Public health
Tag(s): Clinical
Target audience: Adult pulmonologist/Clinician, General practitioner, Medical Student, Nurse, Paediatrician, Physician in Pulmonary Training, Respiratory physiotherapist, Journalist

00:00  Successfully managing adolescent and young adult patients with asthma
Graham Roberts (Southampton (Hampshire), United Kingdom)

Pre-congress content  Session  00:00 - 23:59
Expert view: Extracorporeal life support in lung failure and lung transplant bridging: when and how

Aims: To describe invasive mechanical respiratory support, including mechanical ventilation and/or extracorporeal life support (ECLS), that has become common practice in patients with acute cardiopulmonary failure or for bridging to lung transplantation; to describe technical and ethical challenges associated with ECLS; to evaluate technical expertise, knowledge of candidate selection, transplant referral guidelines and organ allocation systems crucial to achieve acceptable results in patients on ECLS; and to describe the aims, indications, contra-indications, principles and complications of ECLS.

Disease(s): Respiratory critical care
Method(s): Respiratory intensive care
Tag(s): Clinical
Target audience: Adult pulmonologist/Clinician, General practitioner, Medical Student, Nurse, Paediatrician, Physiologist, Respiratory critical care physician, Respiratory physiotherapist, Thoracic surgeon

00:00  Extracorporeal life support in lung failure and lung transplant bridging: when and how
Arne Neyrinck (Leuven, Belgium)
### Expert view: Physiotherapy in chronic respiratory infections

**Aims:** To evaluate the ability of respiratory physiotherapy to prevent exacerbations and reduce the impact of chronic infections in patients with chronic respiratory diseases, including COPD, bronchiectasis, asthma and cystic fibrosis.

**Disease(s):** Airway diseases, Respiratory infections

**Method(s):** General respiratory patient care, Pulmonary rehabilitation

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Patient, Respiratory physiotherapist, Journalist

**00:00**  
Physiotherapy in chronic respiratory infections  
Arietta Spinou (London, United Kingdom)

### Expert view: Optimal treatment for multistage N2-disease

**Aims:** To determine the prognosis of patients with stage III NSCLC and ipsilateral lymph nodes; to differentiate among types of N2 disease; to describe the different treatment modalities (surgery plus chemotherapy; surgery, chemotherapy and radiotherapy; radiochemotherapy, and radiochemotherapy plus PD-L1 inhibition) and their advantages and disadvantages in specific situations; to assess the relevance of a multidisciplinary tumour board for these patients; and to describe future developments in immunology.

**Disease(s):** Thoracic oncology

**Method(s):** Endoscopy and interventional pulmonology, Imaging, Surgery

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Pathologist, Radiologist, Thoracic oncologist, Thoracic surgeon

**00:00**  
The optimal treatment for multistage N2-disease

### Expert view: From life threatening to chronic connective tissue disease-associated interstitial lung disease (CTD-ILD): all you need to know

**Aims:** To evaluate interstitial lung disease associated with connective tissue disease (CTD-ILD) as a major cause of morbidity and mortality; to describe the complex management of these diseases, based on their presentations and patterns, their uncertain disease course and their high morbidity and mortality rates; to review the management of life-threatening acute and subacute CTD/ILD, including medical and ICU management; to describe the treatment of patients with chronically progressive CTD-ILD, including the results of recent and ongoing trials and a suggested approach to management decisions; and to compare and contrast key issues on the management of acute vs. chronic CTD-ILD.

**Disease(s):** Interstitial lung diseases, Respiratory critical care

**Method(s):** General respiratory patient care, Imaging, Respiratory intensive care

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Respiratory therapist, Medical Student, Nurse, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory critical care physician, Respiratory physiotherapist, Scientist (basic, translational)

**00:00**  
From life threatening to chronic connective tissue disease-associated interstitial lung disease: all you need to know  
Sonye Danoff (Baltimore, United States of America)

### Expert view: Treatment in pulmonary hypertension

**Aims:** To describe updated treatment algorithms in pulmonary hypertension; to evaluate treatments of chronic thromboembolic pulmonary hypertension; and to determine when to treat or not to treat pulmonary hypertension.

**Disease(s):** Pulmonary vascular diseases

**Method(s):** General respiratory patient care

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, General practitioner, Medical Student, Nurse, Physician in Pulmonary Training, Thoracic surgeon
<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of pulmonary hypertension</td>
<td>00:00 - 23:59</td>
<td>Expert view: Transbronchial cryobiopsy in diffuse parenchymal lung diseases</td>
</tr>
<tr>
<td>Aims: To evaluate appropriate biopsy methods for the diagnosis of interstitial lung diseases; to describe the risks of and indications for transbronchial cryobiopsy and to compare the safety and efficacy of this method with other biopsy methods (e.g., transbronchial biopsy with conventional forceps and surgical lung biopsy).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease(s): Interstitial lung diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tag(s): Clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Pathologist, Physician in Pulmonary Training, Thoracic surgeon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transbronchial cryobiopsy in diffuse parenchymal lung diseases</td>
<td>00:00</td>
<td>Expert view: The role of the radiologist in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td>Aims: To describe the use of high-resolution computed tomography (HRCT) in the multidisciplinary approach to patients with diffuse and interstitial lung disease; to describe characteristics on HRCT scans differentiating among definite usual interstitial pneumonia (UIP), probable UIP, indeterminate for UIP and an alternative diagnosis; to describe the role of HRCT in clinical decision making in patients suspected of having idiopathic pulmonary fibrosis (IPF) and to compare ATS/ERS/JRS/ALAT clinical guidelines with the Fleischner Society criteria for the diagnosis of IPF.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease(s): Interstitial lung diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method(s): Imaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tag(s): Clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target audience: Adult pulmonologist/Clinician, Pathologist, Radiologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The role of the radiologist in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis</td>
<td>00:00</td>
<td>Expert view: Managing stable, severe COPD</td>
</tr>
<tr>
<td>Aims: To describe recommendations for management of patients with nonexacerbated but severe COPD, including the identification and reduction of risk factors; to describe pharmacologic and nonpharmacologic treatment modalities and their outcomes; to describe the use of step-up and step-down treatment approaches; and to emphasise the important role of evaluating and managing comorbidities, especially for cardiovascular diseases, as well as the use of polypharmacy, in patients with severe COPD.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease(s): Airway diseases, Respiratory critical care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method(s): General respiratory patient care, Palliative care, Pulmonary rehabilitation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tag(s): Clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Respiratory critical care physician, Journalist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Managing stable, severe COPD</td>
<td>00:00</td>
<td>Expert view: Common variable immunodeficiency (CVID)</td>
</tr>
<tr>
<td>Common variable immunodeficiency (CVID)</td>
<td>00:00</td>
<td>Expert view: Gender-based differences in drug toxicity</td>
</tr>
<tr>
<td>Gender-based differences in drug toxicity</td>
<td>00:00</td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>Expert view</td>
<td>Session</td>
<td>00:00 - 23:59</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Changing to Global Lung Function Initiative (GLI) reference will help my patient</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> Changing to Global Lung Function Initiative (GLI) reference will help my patient</td>
<td>Brendan Cooper (Edgbaston (Birmingham), United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Challenge and success in a patient centered Clinical Research Collaboration</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> Challenge and success in a patient centered Clinical Research Collaboration</td>
<td>Dominique Hamerlijnck (Amsterdam, Netherlands), Ratko Djukanovic (Southampton (Hampshire), United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Palliative care in tuberculosis</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> Palliative care in tuberculosis</td>
<td>Graham H. Bothamley (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Do we really need guidelines?</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> Do we really need guidelines?</td>
<td>Speaker to be confirmed</td>
<td></td>
</tr>
<tr>
<td>CRISPR for dummies</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> CRISPR for dummies</td>
<td>Alen Faiz (Ultimo (NSW), Australia)</td>
<td></td>
</tr>
<tr>
<td>The role of patients in medicine</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> The role of patients in medicine</td>
<td>Isabel Saraiva (Cascais, Portugal), Kjeld Hansen (Oslo, Norway)</td>
<td></td>
</tr>
<tr>
<td>Genom revolution: Human Lung Cell Atlas</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>06:00</strong> DiscovAIR: Basic science - Human Lung Cell Atlas</td>
<td>Martijn C. Nawijn (Groningen, Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Microplastic in the lungs: should we be worried?</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> Microplastic in the lungs</td>
<td>Frank J. Kelly (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Puzzling natures of the solitary pulmonary nodules that only the pulmonologist can solve</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> Puzzling natures of the solitary pulmonary nodules that only the pulmonologist can solve</td>
<td>Georgia Hardavella (Athens, Greece)</td>
<td></td>
</tr>
<tr>
<td>Replacement of animal models in respiratory medicine</td>
<td><strong>Session</strong></td>
<td>00:00</td>
</tr>
<tr>
<td><strong>00:00</strong> Replacement of animal models in respiratory medicine</td>
<td>Pieter S. Hiemstra (Leiden, Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>
### Pre-congress content

#### Session 00:00 - 23:59

**Expert view: Preprints: growth and evolution in the medical publishing space**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>00:00</td>
<td>Preprints: growth and evolution in the medical publishing space</td>
<td>Martin Kolb (Hamilton (ON), Canada)</td>
</tr>
</tbody>
</table>

**Aims:**

- to be able to name and compare advantages and challenges of the holistic versus the fragmented care pathways of lung cancer.
- to discuss who should be in charge of the care of lung cancer patients and whether pulmonologists are enough trained into the art of modern oncology to keep pace with a rapidly changing spectrum of molecular tests and targeted treatments.

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>00:00</td>
<td>Lung cancer or cancer of the lung: a view from the bridge</td>
<td>Pieter E. Postmus (LEIDEN, Netherlands)</td>
</tr>
</tbody>
</table>

**Pre-congress content**

**Session 00:00 - 23:59**

**Expert view: Burning up while burning out: compassion fatigue awareness and burnout prevention for practitioners**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>00:00</td>
<td>Burning up while burning out: compassion fatigue awareness and burnout prevention for practitioners</td>
<td>Howard Baumgarten (Denver, United States of America)</td>
</tr>
</tbody>
</table>

**Pre-congress content**

**Session 00:00 - 23:59**

**Expert view: AI: are the doctors still needed?**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>00:00</td>
<td>AI: are the doctors still needed?</td>
<td>Speaker to be confirmed</td>
</tr>
</tbody>
</table>
ERS 2020 International Congress

DETAILED PROGRAMME
SUNDAY 06 SEPTEMBER, 2020

Channel 1  Session  13:15 - 14:15
Assembly members' meeting: Assembly 1: General pneumology
Chairs: Hilary Pinnock (Edinburgh, United Kingdom), Ioannis Vogiatzis (Newcastle upon Tyne, United Kingdom)

Channel 4  Session  13:15 - 14:15
Assembly members' meeting: Assembly 4: Sleep and breathing disorders; and clinical physiology
Chairs: Andrea Aliverti (Milan, Italy), Pierantonio Laveneziana (Paris, France)

Channel 7  Session  13:15 - 14:15
Assembly members' meeting: Assembly 7: Paediatrics
Chairs: Marielle W.H. Pijnenburg (Rotterdam, Netherlands), Jonathan Grigg (London, United Kingdom)

Channel 2  Session  13:15 - 14:15
Assembly members' meeting: Assembly 2: Respiratory intensive care
Chairs: Marcus Schultz (Amsterdam, Netherlands), Leo Heunks (Amsterdam, Netherlands)

Channel 3  Session  13:15 - 14:15
Assembly members' meeting: Assembly 3: Basic and translational sciences
Chairs: Catherine Greene (Dublin 9, Ireland), Silke Meiners (München, Germany)

Channel 5  Session  13:15 - 14:15
Assembly members' meeting: Assembly 5: Airway diseases, asthma and COPD
Chairs: Omar S. Usmani (London, United Kingdom), Antonio Spanevello (Milan, Italy)

Channel 6  Session  13:15 - 14:15
Assembly members' meeting: Assembly 6: Epidemiology and environment
Chairs: Christer Janson (Uppsala, Sweden), Charlotte Suppli Ulrik (Virum, Denmark)

Channel 2  Session  14:30 - 15:30
Assembly members' meeting: Assembly 9: Allied respiratory professionals
Chairs: Martijn A. Spruit (Horn, Netherlands), Daniel Langer (Leuven, Belgium)

Channel 1  Session  14:30 - 15:30
Assembly members' meeting: Assembly 8: Thoracic surgery and transplantation
Chairs: Federica Meloni (Pavia (PV), Italy), Stefano Elia (Roma (RM), Italy)

Channel 5  Session  14:30 - 15:30
Assembly members' meeting: Assembly 12: Interstitial lung diseases
Chairs: Venerino Poletti (Forlì, Italy), Katerina Antoniou (Heraklion, Greece)

Channel 6  Session  14:30 - 15:30
Assembly members' meeting: Assembly 13: Pulmonary vascular diseases
Chairs: Anton Vonk Noordegraaf (Amsterdam, Netherlands), Marion Delcroix (Leuven, Belgium)

Channel 4  Session  14:30 - 15:30
Assembly members' meeting: Assembly 11: Thoracic oncology
Chairs: Torsten Gerriet Blum (Berlin, Germany), Jan van Meerbeeck (Edegem (Antwerp), Belgium)

Channel 7  Session  14:30 - 15:30
Assembly members' meeting: Assembly 14: Clinical techniques, imaging and endoscopy
Chairs: Jouke T. Annema (Amsterdam, Netherlands), Walter De Wever (Leuven, Belgium)
## Channel 3  
### Session  
14:30 - 15:30  

**Assembly members' meeting: Assembly 10: Respiratory infections**  

**Chairs:** Eva Polverino (Barcelona, Spain), Graham H. Bothamley (London, United Kingdom)
Studio Paris: Session 09:30 - 10:30
Symposium: New developments in pandemic medicine
An update from the PREPARE EU research project

**Aims:** To describe the latest developments in antiviral therapy for influenza and the growing clinical problem of arbovirus infection in Europe; to evaluate the rationale for adaptive trials investigating critical care interventions in a pandemic; and to describe a collaborative strategy for increasing clinical and research capacity in Europe for pandemic care.

**Disease(s):** Respiratory infections

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Respiratory critical care physician, Pathologist, Physician in Pulmonary Training, Respiratory physiotherapist, Scientist (basic, translational)

**Chairs:** Tobias Welte (Hannover, Germany)

09:30 | Introduction
09:35 | Antiviral therapy for influenza: latest trial results
      | Christopher Butler (Oxford (Oxfordshire), United Kingdom)
09:45 | New approaches to designing trials for pandemics: setting up an adaptive trial for management strategies in community acquired pneumonia
      | Lennie P. G. Derde (Utrecht, Netherlands)
09:55 | ISARIC Covid-19 pandemic research response, tools and outcomes from clinical characterisation studies
      | Louise Sigfrid (Brighton (East Sussex), United Kingdom)
10:05 | Developing a pandemic strategy: building long-term research capacity and resilience in Europe
      | Speaker to be confirmed
10:15 | Discussion and Q&A

Studio Vienna: Session 09:30 - 11:40
Grand round: Imaging grand round
Emerging imaging technologies and innovative study fields in respiratory diseases

**Aims:** To describe the latest advances in imaging technology with a focus on diagnosis of early disease and prevention; to evaluate the role of artificial intelligence in imaging and the integration of artificial intelligence with emerging imaging techniques, such as magnetic resonance imaging (MRI) and quantitative computed tomography (CT), as well as deep learning; to evaluate the use of radiogenomics in classifying patients who will benefit from cancer treatment and predict outcomes using texture analysis; and to describe the results of imaging twin studies in estimating the role of genetic, epigenetic and environmental effects on respiratory diseases.

**Disease(s):** Airway diseases, Interstitial lung diseases, Thoracic oncology

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Respiratory critical care physician, Paediatrician, Radiologist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon, Journalist

**Chairs:** Daiana Stolz (Basel, Switzerland), Walter De Wever (Leuven, Belgium), Chair to be confirmed

09:30 | Introduction
09:35 | Deep learning and its applications to lung imaging
      | Maria Vakalopoulou (Saint-Aubin, France)
09:55 | Discussion and Q&A
      | Maria Vakalopoulou (Saint-Aubin, France)
10:05 | Artificial intelligence in lung cancer: where are we now?
      | Speaker to be confirmed
10:25 | Discussion and Q&A
      | Speaker to be confirmed
10:35 | The future is here in thoracic oncologic imaging: role of radiogenomics
      | Speaker to be confirmed
10:55 | Discussion and Q&A
      | Speaker to be confirmed
11:05 Imaging twin studies to unravel the genetic, epigenetic and environmental background of lung diseases
Adám Domonkos Tárnoki (Budapest, Hungary), David Laszlo Tarnoki (Budapest, Hungary)

11:25 Discussion and Q & A
Adám Domonkos Tárnoki (Budapest, Hungary), David Laszlo Tarnoki (Budapest, Hungary)

Channel 1 Session 09:30 - 11:00
Language session: Chinese programme 2020: Part I
Joint ERS/CTS session

Aims: To allow experienced speakers from the ERS leadership and Chinese leaders in respiratory medicine to describe new advances in respiratory medicine; and to present an overview of respiratory diseases, including early diagnosis, public health, sleep, and pulmonary embolism, in Europe and China.

Disease(s): [Airway diseases] [Pulmonary vascular diseases] [Sleep and breathing disorders]

Tag(s): Clinical

Target audience: Adult pulmonologist/ Clinician, Clinical researcher, General practitioner, Nurse, Scientist (basic, translational), Thoracic oncologist

Chairs: Rongchang Chen (Guangzhou (Guangdong), China), Ayşe Arzu Yorgancıoğlu (Izmir, Turkey)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:35</td>
<td>Strategy for early diagnosis and intervention in chronic respiratory disease</td>
</tr>
<tr>
<td></td>
<td>Nanshan Zhong (Guangzhou (Guangdong), China)</td>
</tr>
<tr>
<td>09:45</td>
<td>Global Alliance Against Chronic Respiratory Diseases (GARD): Beijing call to action to promote lung health</td>
</tr>
<tr>
<td></td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>09:55</td>
<td>A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir-ritonavir in adults hospitalized with COVID-19 virus infection</td>
</tr>
<tr>
<td></td>
<td>BIN CAO (BEIJING, China)</td>
</tr>
<tr>
<td>10:05</td>
<td>Lessons shared and perspectives in mechanical ventilation for COVID-19</td>
</tr>
<tr>
<td></td>
<td>Anita Simonds (London, United Kingdom)</td>
</tr>
<tr>
<td>10:15</td>
<td>ERS advocacy priorities: air pollution, lung cancer screening, new nicotine delivery products and others</td>
</tr>
<tr>
<td></td>
<td>Ayşe Arzu Yorgancıoğlu (Izmir, Turkey)</td>
</tr>
<tr>
<td>10:25</td>
<td>Outdoor air pollution and the burden of childhood asthma across Europe</td>
</tr>
<tr>
<td></td>
<td>David Rojas-Rueda (Barcelona, Spain)</td>
</tr>
<tr>
<td>10:35</td>
<td>Discussion and Q &amp; A</td>
</tr>
</tbody>
</table>

Studio Madrid Session 09:30 - 10:30
State of the art session: Paediatric respiratory diseases

Aims: To describe current information about four important paediatric respiratory areas and to highlight future changes in diagnosis and management.

Disease(s): [Airway diseases] [Paediatric respiratory diseases] [Sleep and breathing disorders]

Tag(s): Clinical

Target audience: Clinical researcher, Medical Student, Nurse, Paediatrician, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist

Chairs: Marielle W.H. Pijnenburg (Rotterdam, Netherlands), Ernst Eber (Graz, Austria)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:35</td>
<td>Congenital malformations</td>
</tr>
<tr>
<td></td>
<td>Petr Pohunek (Praha, Czech Republic)</td>
</tr>
<tr>
<td>09:45</td>
<td>Bronchiolitis obliterans</td>
</tr>
<tr>
<td></td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>09:55</td>
<td>Assessing and improving the lung function growth trajectory in infants and children</td>
</tr>
<tr>
<td></td>
<td>Peter D. Sly (Brisbane (QLD), Australia)</td>
</tr>
</tbody>
</table>
### Studio Paris Session 10:40 - 11:40

**Symposium: Antibiotic resistance: the way forward**

**A joint ERS/ESCMID symposium**

**Aims:** To describe factors associated with antibiotic resistance and the use of innate immunity to improve antibiotic effectiveness: to determine the optimal dose of antibiotics to eliminate infections and prevent the development and resistance; and to describe methods of eliminating biofilms.

**Disease(s):** Respiratory infections

**Tag(s):** Translational

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Physician in Pulmonary Training

**Chairs:** Tobias Welte (Hannover, Germany)

**10:40** Introduction

**10:45** Antibiotics kill some but not all pathogens: persistent populations and how they arise  
Speaker to be confirmed

**10:55** Better diagnostics for targeted antibiotic therapy  
Speaker to be confirmed

**11:05** Improving the innate immune response in respiratory infections: the use of repurposed drugs  
Victor Nizet (La Jolla, United States of America)

**11:15** Biofilms and how to combat them: examples from cystic fibrosis  
Speaker to be confirmed

**11:25** Discussion and Q&A

### Studio Madrid Session 10:40 - 11:40

**Symposium: Respiratory diseases in children and adults**

**Aims:** To describe pre- and postnatal early life origins of airway diseases in children and adults; to describe risk factors for the progression of lung disease in patients with cystic fibrosis; and to describe the challenges of lower respiratory tract infections in children and adults.

**Disease(s):** Airway diseases, Paediatric respiratory diseases, Respiratory infections

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Paediatrician, Patient, Physician in Pulmonary Training, Respiratory physiotherapist, Journalist

**Chairs:** Marielle W.H. Pijnenburg (Rotterdam, Netherlands), Ernst Eber (Graz, Austria)

**10:40** Introduction

**10:45** The early life origins of asthma  
Sejal Saglani (London, United Kingdom)

**10:55** The early life origins of chronic obstructive pulmonary disease  
Alvar Agusti Garcia-Navarro (Barcelona, Spain)

**11:05** Risk factors for progression of cystic fibrosis lung disease from childhood to adulthood  
Speaker to be confirmed

**11:15** Lower respiratory tract infections: challenges in children and adults  
Felix C. Ringshausen (Hannover, Germany)

**11:25** Discussion and Q&A

### Channel 4 Session 11:50 - 12:50

**Challenging clinical cases: Interstitial lung diseases**
Aims: To describe the history, pathology, analysis and treatment of complex clinical cases in respiratory critical care. The session leaders will facilitate discussions among the case presenters and audience.

Disease(s): Interstitial lung diseases

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Respiratory critical care physician, Thoracic oncologist, Thoracic surgeon, Nurse, Radiologist

Chairs: Michael Kreuter (Heidelberg, Germany), Maria Molina Molina (Barcelona, Spain)

11:50 Introduction

11:55 Case 1

12:01 Discussion and Q & A

12:06 Case 2

12:12 Discussion and Q & A

12:17 Case 3

12:23 Discussion and Q & A

12:28 Case 4

12:34 Discussion and Q & A

12:39 Case 5

12:45 Discussion and Q & A

---

Symposium: Which paediatric asthma guidelines are the most appropriate for children and adolescents?

Aims: To describe the evidence supporting current international guidelines on treatment of children with asthma steps 1–3 and the dependence of this evidence on healthcare settings; and to describe evidence for individualised/stratified treatment in childhood asthma.

Disease(s): Airway diseases, Paediatric respiratory diseases

Method(s): General respiratory patient care

Tag(s): Clinical

Target audience: Clinical researcher, General practitioner, Respiratory therapist, Medical Student, Nurse, Paediatrician, Patient

Chairs: Marielle W.H. Pijnenburg (Rotterdam, Netherlands), Ernst Eber (Graz, Austria)

11:50 Introduction

11:55 Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?

Louise Fleming (London, United Kingdom)

12:05 Asthma treatment in step 3: the cases for adding LABA or doubling ICS

Stephen Turner (Aberdeen (Aberdeenshire), United Kingdom)

12:15 Comorbidities in asthma: the role of obesity in children with asthma

Erick Forno (Pittsburgh, United States of America)

12:25 From guidelines to personalized treatment of children with asthma

Speaker to be confirmed

12:35 Discussion and Q & A

---

Symposium: Lung cancer screening: are we back to the individualised decision-making process?

Ground glass opacities, subsolid and part-solid nodules: have we returned to individualised decisions about and management of pulmonary nodules?
Aims: To describe the morphology of suspicious nodules and the clinical factors associated with lung cancer risk; and to evaluate the latest guidelines on a multidisciplinary approach to early lung cancer diagnosis and treatment.

Disease(s): Thoracic oncology

Method(s): Endoscopy and interventional pulmonology  Imaging  Surgery

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Medical Student, Pathologist, Radiologist, Thoracic oncologist, Thoracic surgeon

Chairs: Reinoud Gosens (Groningen, Netherlands), Otto Chris Burghuber (Wien, Austria)

11:50  Introduction

11:55  The new perspectives in chest imaging: back to the future?  
Hans-Ulrich Kauczor (Heidelberg, Germany)

12:05  The influence of nodule evaluation on management recommendations  
Georgia Hardavella (Athens, Greece)

12:15  Sublobar resections vs lobectomy for early stage lung cancer: where do we stand?  
René Horsleben Petersen (Copenhagen, Denmark)

12:25  The role of robotic surgical management in early stage lung cancer  
Gulia Veronesi (Milan, Italy)

12:35  Discussion and Q & A

Studio Paris

Journal session: The European Respiratory Journal editor’s view: our best papers of last year

Aims: To present the best papers published in 2019–2020 in the European Respiratory Journal (ERJ) in the fields of paediatric pulmonology, pulmonary infections, thoracic oncology and airways diseases; and to provide experts' opinions about the importance of these articles.

Disease(s):  
Airway diseases  Paediatric respiratory diseases  Respiratory infections

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Paediatrician, Physician in Pulmonary Training, Thoracic oncologist

Chairs: Tobias Welte (Hannover, Germany)

11:50  Introduction  
Martin Kolb (Hamilton (ON), Canada)

11:55  The best papers in the ERJ: infectious diseases in the respiratory system  
Grant Waterer (Perth (WA), Australia)

12:05  The best papers in the ERJ: paediatric pulmonary diseases  
Claudia E. Kuehni (Bern, Switzerland)

12:15  The best papers in the ERJ: chronic airways diseases, including asthma and COPD  
Mina Gaga (Athens, Greece)

12:25  The best papers in the ERJ: malignant thoracic disorders  
Jose Porcel (Lleida, Spain)

12:35  Discussion and Q & A

12:45  Conclusion  
Martin Kolb (Hamilton (ON), Canada)

Studio Vienna

Lungs on fire: Airway diseases?

Aims: To describe real-life clinical cases during the innovative interactive session, including the presentation of cases that have various levels of difficulty and often necessitate a differential diagnosis. This session will be led by a discussant, who will present the cases to a panel of experts and the audience. The discussant will encourage discussion among the panel of experts, who are encountering these cases for the first time. To further determine diagnostic and therapeutic options for these patients, the discussant will also invite audience participation in the reflection and discussion of these cases.
**Channel 1**

**Session**

**Respiratory medicine meets other disciplines: Breathing disorders and cardiovascular diseases**

A joint ESC/ERS session

**Aims:** To describe the need for intense collaboration among pneumologists, cardiologists and intensive care specialists for the proper care of patients with pulmonary hypertension.

**Disease(s):** Pulmonary vascular diseases

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Respiratory critical care physician, Physician in Pulmonary Training

**Chairs:** Olivier Sitbon (Le Kremlin-Bicêtre, France), Chair to be confirmed

**Discussants:** Dave Singh (Manchester, United Kingdom)

**11:50** Introduction and presentation by the session facilitator

Dave Singh (Manchester, United Kingdom)

**11:54** Case 1

**12:04** Discussion and Q & A

**12:08** Case 2

**12:18** Discussion and Q & A

**12:22** Case 3

**12:32** Discussion and Q & A

**12:36** Case 4

**12:46** Discussion and Q & A

---

**Channel 4**

**Session**

**Challenging clinical cases: Respiratory infections**

**Aims:** To describe the history, pathology, analysis and treatment of complex clinical cases in respiratory critical care. The session leaders will facilitate discussions among the case presenters and audience.

**Disease(s):** Respiratory infections

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Respiratory critical care physician, General practitioner, Clinical researcher, Paediatrician, Thoracic surgeon, Nurse, Respiratory physiotherapist

**Chairs:** Eva Polverino (Barcelona, Spain), Chair to be confirmed

**11:50** Introduction

**11:55** Keeping the kidney and heart in balance: management of end-stage right heart failure

Laurent Savale (Le Kremlin-Bicêtre, France)

**12:05** Interventional treatment of pulmonary hypertension: where are we now?

Nazzareno Galiè (Bologna (BO), Italy)

**12:15** Journeys to high altitude: risks and recommendations for travellers with/without pre-existing cardiopulmonary conditions

Konrad E. Bloch (Zurich, Switzerland)

**12:25** ERS statement on chronic thromboembolic pulmonary hypertension

Marion Delcroix (Leuven, Belgium)

**12:35** Discussion and Q & A
Studio Milan  
Session  
14:30 - 15:30

Symposium: Image-based guidelines and recommendations in respiratory diseases

Aims: To describe how to use guidelines and recommendations in the management of screen-based and incidentally identified nodules and how to use revised guidelines to evaluate the results of high-resolution computed tomography (HRCT) in the diagnosis of idiopathic pulmonary fibrosis (IPF) and its place in the clinical work-up of patients with this disease; and to describe the use of appropriate imaging modalities in the staging of lung cancer and in the diagnosis of pulmonary embolism and pulmonary hypertension.

Disease(s): Interstitial lung diseases, Pulmonary vascular diseases, Thoracic oncology

Method(s): General respiratory patient care, Imaging

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, General practitioner, Respiratory therapist, Medical Student, Nurse, Paediatrician, Pathologist, Radiologist, Respiratory critical care physician, Thoracic oncologist, Thoracic surgeon

Chairs: Mina Gaga (Athens, Greece), Jan van Meerbeeck (Edegem (Antwerp), Belgium)

14:30  Introduction

14:35  Case 1

14:41  Discussion and Q & A

14:46  Case 2

14:52  Discussion and Q & A

14:57  Case 3

15:03  Discussion and Q & A

15:08  Case 4

15:14  Discussion and Q & A

15:19  Case 5

15:25  Discussion and Q & A
ERS Statement: Global Lung Function Initiative (GLI): Deriving global multi-ethnic reference values for the measurement of lung volumes
Sanja Stanojevic (Halifax (NS), Canada)

The evolution of respiratory function testing in paediatric lung diseases
Laura Graciela Gochicoa Rangel (Ciudad de México, Mexico)

Challenging spirometry with newer lung function tests in adults
Omar S. Usmani (London, United Kingdom)

Applying new respiratory function technologies to the elderly and the potential of future lung regeneration
Andrea Aliverti (Milan, Italy)

Discussion and Q&A

Studio Madrid

14:30 - 15:30

Journal session: New technologies for the management of COPD and obstructive sleep apnea and the diagnosis of lung cancer
Highlights from JAMA and the JAMA Network

Aims: To review 1) recent advances in surgical approaches to the treatment of obstructive sleep apnea; 2) recent advances in blood biomarkers in the diagnosis of lung cancer; 3) recent clinical trial evidence on the benefits and risks of in-home noninvasive ventilation for severe COPD.

Disease(s): Airway diseases, Sleep and breathing disorders, Thoracic oncology

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Physician in Pulmonary Training

Chairs: Anita Simonds (London, United Kingdom), Anh Tuan Dinh-Xuan (Paris, France)

14:30 Introduction
George O'Connor (Boston, United States of America)

14:35 Surgical approaches to the treatment of obstructive sleep apnea
Stuart MacKay (Wollongong, Australia)

14:48 Blood biomarkers in the diagnosis of lung cancer
Speaker to be confirmed

15:02 Home noninvasive positive pressure ventilation for severe COPD
Claudia Dobler (Coogee, Australia)

15:15 Discussion and Q&A

15:25 Conclusion
George O'Connor (Boston, United States of America)

Lungs on fire: Interstitial lung diseases?

Aims: To describe real-life clinical cases during the innovative interactive session, including the presentation of cases that have various levels of difficulty and often necessitate a differential diagnosis. This session will be led by a discussant, who will present the cases to a panel of experts and the audience. The discussant will encourage discussion among the panel of experts, who are encountering these cases for the first time. To further determine diagnostic and therapeutic options for these patients, the discussant will also invite audience participation in the reflection and discussion of these cases.

Disease(s): Interstitial lung diseases, Respiratory infections

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Thoracic surgeon, Thoracic oncologist, General practitioner, Paediatrician, Nurse, Clinical researcher, Radiologist, Respiratory critical care physician

Chairs: Richard Costello (Dublin 9, Ireland), Katerina Antoniou (Heraklion, Greece), Marc Humbert (Le Kremlin-Bicêtre, France)

Discussants: Nazia Chaudhuri (Manchester (Greater Manchester), United Kingdom)
### Challenging clinical cases: Respiratory critical care

**Aims:** To describe the history, pathology, analysis and treatment of complex clinical cases in respiratory critical care. The session leaders will facilitate discussions among the case presenters and audience.

**Disease(s):** Respiratory critical care  
**Tag(s):** Clinical  
**Target audience:** Adult pulmonologist/Clinician, Respiratory critical care physician, Clinical researcher, General practitioner, Paediatrician, Thoracic oncologist, Thoracic surgeon, Pathologist, Nurse, Radiologist  
**Chairs:** Marieke L. Duiverman (Groningen, Netherlands), Enrico M. Clini (Modena (MO), Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>Case 1</td>
</tr>
<tr>
<td>14:51</td>
<td>Discussion and Q&amp;A</td>
</tr>
<tr>
<td>14:56</td>
<td>Case 2</td>
</tr>
<tr>
<td>15:02</td>
<td>Discussion and Q&amp;A</td>
</tr>
<tr>
<td>15:07</td>
<td>Case 3</td>
</tr>
<tr>
<td>15:13</td>
<td>Discussion and Q&amp;A</td>
</tr>
<tr>
<td>15:18</td>
<td>Case 4</td>
</tr>
<tr>
<td>15:24</td>
<td>Discussion and Q&amp;A</td>
</tr>
<tr>
<td>15:29</td>
<td>Case 5</td>
</tr>
<tr>
<td>15:35</td>
<td>Discussion and Q&amp;A</td>
</tr>
<tr>
<td>15:40</td>
<td>Introduction</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>15:40</td>
<td>Introduction</td>
</tr>
<tr>
<td>15:45</td>
<td>The challenge for the endoscopist</td>
</tr>
<tr>
<td></td>
<td>Erik H.F.M. van der Heijden (Nijmegen, Netherlands)</td>
</tr>
<tr>
<td>15:55</td>
<td>Issues other than tissue: non-invasive biomarkers of early stage lung cancer</td>
</tr>
<tr>
<td></td>
<td>Torsten Gerriet Blum (Berlin, Germany)</td>
</tr>
<tr>
<td>16:05</td>
<td>Radiologic early detection of early thoracic cancers: the role of artificial intelligence</td>
</tr>
<tr>
<td></td>
<td>Wieland Voigt (Berlin, Germany)</td>
</tr>
<tr>
<td>16:15</td>
<td>The challenge for the pathologist and pulmonologist: liquid biopsy in the diagnosis of early stage lung cancer</td>
</tr>
<tr>
<td></td>
<td>Joanna Chorostowska-Wynimko (Warsaw, Poland)</td>
</tr>
<tr>
<td>16:25</td>
<td>Discussion and Q&amp;A</td>
</tr>
</tbody>
</table>

### Symposium: European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases

**Disease(s):** Airway diseases, Interstitial lung diseases, Pulmonary vascular diseases

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Physician in Pulmonary Training, Journalist

**Chairs:** Marlies S. Wijsenbeek (Rotterdam, Netherlands), Chair to be confirmed

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40</td>
<td>Introduction</td>
</tr>
<tr>
<td>15:45</td>
<td>ERN-lung report from the network coordination team</td>
</tr>
<tr>
<td></td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>15:54</td>
<td>Phenotypic Spectrum in Primary Ciliary Dyskinesia</td>
</tr>
<tr>
<td></td>
<td>Heymut Omran (Münster, Germany)</td>
</tr>
<tr>
<td>16:03</td>
<td>Genomically-guided therapies: a new era for cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td>Marcus Mall (Berlin, Germany)</td>
</tr>
<tr>
<td>16:12</td>
<td>Why should we care for the vessels in interstitial lung disease?</td>
</tr>
<tr>
<td></td>
<td>Horst Olschewski (Graz, Austria)</td>
</tr>
<tr>
<td>16:21</td>
<td>Immundefects, rare pulmonary infections and rare lung diseases</td>
</tr>
<tr>
<td></td>
<td>John R Hurst (London, United Kingdom)</td>
</tr>
<tr>
<td>16:30</td>
<td>Discussion and Q&amp;A</td>
</tr>
</tbody>
</table>

### Studio Paris

**Hot topics: Innovations in airway innervation: treatments for chronic cough**

**Aims:** To better understand 1) the innervation of the airways and how novel therapies may act on airway nerves; 2) the concept of cough reflex hypersensitivity and how that may manifest in clinical diseases, not only chronic cough patients but also in chronic respiratory diseases; 3) the mechanism of action, potential clinical effects and utility of a range of P2X3 antagonists in development; the mechanism of action, potential clinical effects and utility of other new anti-tussive therapies currently in development.

**Disease(s):** Airway diseases

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist

**Chairs:** Thomas Geiser (Bern, Switzerland), Ay e Arzu Yorganc o lu (Izmir, Turkey)
Differential diagnosis of chronic cough  
Imran Satia (Hamilton (ON), Canada)

Cough reflex hypersensitivity: a treatable trait?  
Speaker to be confirmed

Novel treatments of chronic cough  
Jaclyn Smith (Manchester (Greater Manchester), United Kingdom)

Discussion and Q&A

State of the art session: Sleep and breathing disorders  
From screening to optimal management

Introduction

The Sadoul Lecture: Obstructive sleep apnea - past, present, and future  
Maria Bonsignore (Palermo, Italy)

Screening for sleep disordered breathing: in whom and how  
Sophia E. Schiza (Heraklion, Greece)

Personalized treatment in sleep disordered breathing  
Winfried J. Randerath (Solingen, Germany)

Sleep disordered breathing, CVD and Continuous Positive Airway Pressure  
Speaker to be confirmed

ERS statement on sleepiness and fitness to drive in patients with obstructive sleep apnoea  
Walter McNicholas (Dublin, Ireland)

Discussion and Q&A

Symposium: Chronic respiratory diseases and their origins in early life: how physiology meets clinical medicine

Introduction

Early life influences on the development of chronic pulmonary diseases: the role of the paediatrician  
Speaker to be confirmed
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 17:05  | Early origins of chronic pulmonary disease: the role of the adult pulmonologist  
|        | Speaker to be confirmed                                                |
| 17:15  | Effects of lung development on pulmonary function tests: from early life to chronic respiratory disease  
|        | Elianne J.L.E. Vrijlandt (Groningen, Netherlands)                     |
| 17:25  | Pulmonary diseases and ageing                                           
|        | Maria Rosa Faner Canet (Barcelona, Spain)                             |
| 17:35  | Discussion and Q & A                                                   |

Channel 1  
Session 16:50 - 17:50  
Respiratory medicine meets other disciplines: Rheumatology: understanding connective tissue disease in patients with interstitial lung disease  
A joint ERS/European League Against Rheumatism (EULAR) session  
**Aims**: To describe a diagnostic approach for patients presenting with respiratory symptoms and suspected connective tissue disease (CTD); to evaluate the evidence associated with indications for biopsy, including determining preferences for cryobiopsy versus video-assisted thoracoscopic surgery (VATS); and to determine the benefits and revise recommendation for therapy in CTD, including indications for monoclonal antibody (AB) therapy, particularly rituximab.  
**Disease(s)**: Interstitial lung diseases  
**Tag(s)**: Clinical  
**Target audience**: Adult pulmonologist/Clinician, Clinical researcher, Nurse, Physician in Pulmonary Training, Physiologist  
**Chairs**: Michael Tamm (Basel, Switzerland), Gabriela Riemekasten (Lübeck, Germany)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 16:55  | Interstitial lung disease (ILD) and multicompartiment assessment of CTD: where should the respiratory physician begin?  
|        | Christopher P. Denton (London, United Kingdom)                      |
| 17:05  | Does histology matter in ILD-CTD?                                    
|        | Venerino Poletti (Forlì, Italy)                                      |
| 17:15  | Fibrotic CTD and interstitial pneumonia with autoimmune features (IPAF): immunosuppressive or/and anti-fibrotic treatment?  
|        | Sonye Danoff (Baltimore, United States of America)                  |
| 17:25  | B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all?  
|        | Diego Kyburz (Basel, Switzerland)                                    |
| 17:35  | Discussion and Q & A                                                 |

Studio Milan  
Session 16:50 - 17:50  
Live from the clinic: Paediatric procedures  
**Chairs**: Marielle W.H. Pijnenburg (Rotterdam, Netherlands)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50</td>
<td>Introduction</td>
</tr>
</tbody>
</table>

Studio Vienna  
Session 17:20 - 17:50  
Pro/Con debate: Does the global warming potential of propellants in metered dose inhalers matter?  
**Chairs**: Richard Costello (Dublin 9, Ireland), Katerina Antoniou (Heraklion, Greece), Marc Humbert (Le Kremlin-Bicêtre, France)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 17:20  | Pro                                                                   
|        | Omar S. Usmani (London, United Kingdom)                              |
| 17:30  | Con                                                                   
|        | Christer Janson (Uppsala, Sweden)                                    |
| 17:40  | Discussion                                                            
|        | Omar S. Usmani (London, United Kingdom), Christer Janson (Uppsala, Sweden) |

Studio Madrid  
Session 18:00 - 19:00  
Symposium: Exercise and sleep: from impaired function to new therapeutic strategies
Aims: To describe interactions between sleep and exercise from healthy subjects to patients; to evaluate the effects of exercise testing and training on several important pathophysiological mechanisms associated with sleep disorders; and to describe the use of physical activity and exercise as parts of a multi-component individualised strategy to manage sleep disorders.

Disease(s): Paediatric respiratory diseases  Sleep and breathing disorders

Method(s): Physiology  Pulmonary function testing  Pulmonary rehabilitation

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Patient, Physiologist, Respiratory physiotherapist, Scientist (basic, translational)

Chairs: Anita Simonds (London, United Kingdom), Anh Tuan Dinh-Xuan (Paris, France)

18:00 Introduction

18:05 Exercise responses in patients with sleep apnoea
   Ludger Grote (Göteborg, Sweden)

18:15 Circadian rhythm, sleep and exercise

18:25 Blood pressure and exercise in sleep apnoea
   Maria Bonsignore (Palermo, Italy)

18:35 Physical activity and exercise training as therapeutic interventions for sleep apnoea
   Monique Mendelson (Grenoble, France)

18:45 Discussion and Q&A

---

Hot topics: Rethinking Asthma

Aims: To give insights into the management strategy and new treatments across the spectrum of asthma; to present evolution in our understanding of asthma phenotypes and endotypes and their relevance in daily clinical practice.

Disease(s): Airway diseases

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Physiologist

Chairs: Ay e Arzu Yorganc o lu (Izmir, Turkey), Thomas Geiser (Bern, Switzerland)

18:00 Introduction

18:05 Refining asthma treatment for mild asthma
   Roland Buhl (Mainz, Germany)

18:14 Identifying patients with severe asthma that will be benefit from biological therapy
   Celeste Michala Porsbjerg (Copenhagen, Denmark)

18:23 What is it about responders and non-responders in asthma? From biology to physiology and treatment
   Marco Idzko (Wien, Austria)

18:32 Is severe neutrophilic asthma a separate entity?: Pro
   Anke-Hilse Maitland-van der Zee (Amsterdam, Netherlands)

18:41 Is severe neutrophilic asthma a separate entity?: Con
   Speaker to be confirmed

19:00 Discussion and Q&A

---

Lungs on fire: Pulmonary vascular diseases?

Aims: To describe real-life clinical cases during the innovative interactive session, including the presentation of cases that have various levels of difficulty and often necessitate a differential diagnosis. This session will be led by a discussant, who will present the cases to a panel of experts and the audience. The discussant will encourage discussion among the panel of experts, who are encountering these cases for the first time. To further determine diagnostic and therapeutic options for these patients, the discussant will also invite audience participation in the reflexion and discussion of these cases.
**Disease(s):** Pulmonary vascular diseases, Respiratory infections

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Thoracic surgeon, Radiologist, Nurse, Respiratory critical care physician

**Chairs:** Richard Costello (Dublin 9, Ireland), Katerina Antoniou (Heraklion, Greece), Marc Humbert (Le Kremlin-Bicêtre, France)

**Discussants:** Joanna Pepke-Zaba (Cambridge (Cambridgeshire), United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Discussant(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td>Introduction and presentation by the session facilitator</td>
<td>Joanna Pepke-Zaba (Cambridge (Cambridgeshire), United Kingdom)</td>
</tr>
<tr>
<td>18:04</td>
<td>Case 1</td>
<td></td>
</tr>
<tr>
<td>18:14</td>
<td>Discussion and Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>18:18</td>
<td>Case 2</td>
<td></td>
</tr>
<tr>
<td>18:28</td>
<td>Discussion and Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>18:32</td>
<td>Case 3</td>
<td></td>
</tr>
<tr>
<td>18:42</td>
<td>Discussion and Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>18:46</td>
<td>Case 4</td>
<td></td>
</tr>
<tr>
<td>18:56</td>
<td>Discussion and Q &amp; A</td>
<td></td>
</tr>
</tbody>
</table>
Studio Vienna
Session 09:30 - 11:40

Grand round: Clinical grand round

Disease(s): Pulmonary vascular diseases, Thoracic oncology, Respiratory infections, Airway diseases

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Physician in Pulmonary Training, Medical Student

Chairs: Daiana Stolz (Basel, Switzerland), Omar S. Usmani (London, United Kingdom), Chair to be confirmed

09:30 Introduction

09:35 Guidelines on Chronic Refractory Cough
Kian Fan Chung (London, United Kingdom)

09:55 Discussion and Q & A
Kian Fan Chung (London, United Kingdom)

10:00 Pneumonia in adults guidelines: diagnosis and management
Tobias Welte (Hannover, Germany)

10:20 Discussion and Q & A
Tobias Welte (Hannover, Germany)

10:25 Non-tuberculous mycobacteria guidelines
Cécile Magis-Escurra (Nijmegen, Netherlands)

10:45 Discussion and Q & A
Cécile Magis-Escurra (Nijmegen, Netherlands)

10:50 Clinical guidelines on fitness for radical therapy in lung cancer patients
Ales Rozman (Golnik, Slovenia)

11:10 Discussion and Q & A
Ales Rozman (Golnik, Slovenia)

11:15 Guidelines on Acute Pulmonary Embolism
David Jiménez Castro (Madrid, Spain)

11:35 Discussion and Q & A
David Jiménez Castro (Madrid, Spain)

Studio Milan
Session 09:30 - 10:30

Hot topics: Exciting new developments in lung cancer screening, diagnostics and treatment

Aims: To highlight new perspectives in lung cancer by a bench-to-bedside approach transferring latest scientific knowledge of four relevant topics into upcoming clinical management strategies.

Disease(s): Thoracic oncology

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Pathologist, Physician in Pulmonary Training, Radiologist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon

Chairs: Jan van Meerbeeck (Edegem (Antwerp), Belgium), Federica Meloni (Pavia (PV), Italy)

09:30 Introduction

09:35 The lung cancer microenvironment and the lung microbioma: cross or cease fire?
Hortense Slevogt (Berlin, Germany)

09:45 Immunotherapy in SCLC: small step or leap?
Sebahat Ocak (Yvoir, Belgium)

09:55 Pathologist and pulmonologist at crossroads
Joanna Chorostowska-Wynimko (Warsaw, Poland)

10:05 Non-invasive treatment of dyspnoea and pain in thoracic malignancies re-defined
Dragana M. Jovanović (Beograd, Republic of Serbia)
Journal session: Reducing the burden of asthma

Realising the potential for improvements in asthma management and prevention (a joint ERS/Lancet session)

**Aims:** To describe methods of reducing the burden of asthma, including the need to clearly define non-T2 asthma; to describe developments in the treatment and management of asthma, including strategies to protect people with asthma from the risks associated with exposure to air pollution; and to describe risk and protective factors that could be targeted for the primary prevention of asthma.

**Disease(s):** Airway diseases, Paediatric respiratory diseases

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Paediatrician, Scientist (basic, translational)

**Chairs:** Marc Humbert (Le Kremlin-Bicêtre, France), Wisia A. Wedzicha (London, United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Introduction</td>
<td>Rebecca Craven (London, UK)</td>
</tr>
<tr>
<td>09:35</td>
<td><strong>Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention</strong></td>
<td>Erika von Mutius (München, Germany)</td>
</tr>
<tr>
<td>09:45</td>
<td><strong>Mitigating the effects of air pollution in people with asthma</strong></td>
<td>Frank J. Kelly (London, UK)</td>
</tr>
<tr>
<td>09:55</td>
<td><strong>The genetics of asthma and the promise of genomics-guided drug discovery</strong></td>
<td>Gerard H. Koppelman (Groningen, Netherlands)</td>
</tr>
<tr>
<td>10:05</td>
<td><strong>Management of severe asthma in children</strong></td>
<td>Marielle W.H. Pijnenburg (Rotterdam, Netherlands)</td>
</tr>
<tr>
<td>10:15</td>
<td>Discussion and Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10:25</td>
<td>Conclusion</td>
<td>Rebecca Craven (London, UK)</td>
</tr>
</tbody>
</table>
**Studio Madrid**

**Session**  10:40 - 11:40

**Symposium: Cystic fibrosis: from cradle to old age**

**Managing the challenges of a lifelong condition**

**Aims:** To describe major clinical and translational challenges in caring for patients with cystic fibrosis care in the 21st century; and to describe the pathophysiology and clinical characteristics of cystic fibrosis.

**Disease(s):** Respiratory infections, Paediatric respiratory diseases

**Tag(s):** Clinical, Translational

**Target audience:** Paediatrician, Adult pulmonologist/Clinician, Nurse, Physiologist

**Chairs:** Charlotte Suppli Ulrik (Virum, Denmark), Andrew Bush (London, United Kingdom)

**10:40**  Introduction

**10:45**  Lung inflammation in cystic fibrosis: an overlooked therapeutic target?
Stephen M. Stick (Perth (WA), Australia)

**10:54**  Transition from adolescent to adult care
Trudy Havermans (LEUVEN, Belgium)

**11:03**  Gastrointestinal issues in cystic fibrosis and their relevance to the lungs
Barry Plant (Cork, Ireland)

**11:12**  Comorbidities of advanced diseases in patients with cystic fibrosis
Josje Altenburg (Amsterdam (NH), Netherlands)

**11:21**  Changing demographics of cystic fibrosis and models of care
Stuart Elborn (Belfast (Belfast), United Kingdom)

**11:30**  Discussion and Q & A

---

**Studio Milan**

**Session**  10:40 - 11:40

**Hot topics: Pneumothorax: to drain or not to drain**

**Aims:** To review and discuss the most recent insights in spontaneous pneumothorax management.

**Disease(s):** Airway diseases

**Method(s):** Endoscopy and interventional pulmonology, General respiratory patient care, Imaging

**Tag(s):** Clinical

**Target audience:** General practitioner, Patient, Radiologist, Medical Student, Physician in Pulmonary Training, Adult pulmonologist/Clinician

**Chairs:** Jan van Meerbeeck (Edegem (Antwerp), Belgium), Federica Meloni (Pavia (PV), Italy)

**10:40**  Introduction

**10:45**  No need to treat spontaneous pneumothorax
Speaker to be confirmed

**10:55**  Spontaneous pneumothorax need to be treated
Speaker to be confirmed

**11:05**  Aspiration of pneumothorax
Speaker to be confirmed

**11:15**  Role of surgery in pneumothorax treatment
Speaker to be confirmed

**11:25**  Discussion and Q & A

---

**Channel 1**

**Session**  10:40 - 11:40

**Primary care session: Part I: From symptoms to diagnosis in primary care**

**Aims:** To present methods of choosing the most effective diagnostic work up and management for patients with common respiratory symptoms.
Disease(s): Airway diseases, Interstitial lung diseases, Paediatric respiratory diseases
Tag(s): Clinical
Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Paediatrician, Patient, Physician in Pulmonary Training, Respiratory physiotherapist, Journalist
Chairs: Hilary Pinnock (Edinburgh (Edinburgh), United Kingdom), Chair to be confirmed

10:40 Introduction
10:45 Breathlessness, could it be asthma?
   Mike Thomas (Southampton (Hampshire), United Kingdom)
10:55 Breathlessness, could it be COPD?
   Miguel Román Rodriguez (Palma De Mallorca, Spain)
11:05 Smoking: shady practices of the tobacco industry.
   Speaker to be confirmed
11:15 "No Smoking Week" and other activities that clinicians can do or support
   Lucia Gorreto Lopez (Santa Maria del Cami, Spain)
11:25 Discussion and Q & A

Channel 4 Session 11:50 - 12:50
Challenging clinical cases: Paediatric respiratory diseases
Aims: To describe the history, pathology, analysis and treatment of complex clinical cases in respiratory critical care. The session leaders will facilitate discussions among the case presenters and audience.
Disease(s): Paediatric respiratory diseases
Tag(s): Clinical
Target audience: Paediatrician, General practitioner, Respiratory critical care physician, Clinical researcher, Thoracic oncologist, Nurse, Physiologist, Respiratory physiotherapist, Radiologist, Thoracic surgeon
Chairs: Angela Zacharasiewicz (Wien, Austria), Fabio Midulla (Roma (RM), Italy)

11:50 Introduction
11:55 Case 1
12:01 Discussion and Q & A
12:06 Case 2
12:12 Discussion and Q & A
12:17 Case 3
12:23 Discussion and Q & A
12:28 Case 4
12:34 Discussion and Q & A
12:39 Case 5
12:45 Discussion and Q & A

Studio Milan Session 11:50 - 12:50
Symposium: Lung transplantation in the era of new drugs
Aims: To describe the effects of new therapeutic strategies in patients with pulmonary hypertension (PH), interstitial lung diseases (ILD) and cystic fibrosis (CF) on needs and indications for lung transplantation; and to evaluate outcomes of lung transplantation for these three indications.
### Introduction

**The need for lung transplantation in cystic fibrosis (CF) in the era of new treatment**

Christian Benden (Berne, Switzerland)

**New antifibrotic drugs: will interstitial diseases patients still need lung transplantation?**

Claudia Valenzuela (Madrid, Spain)

**New issues in lung transplantation for pulmonary hypertension**

Marion Delcroix (Leuven, Belgium)

**Figures and outcomes of lung transplantation**

Jens Gottlieb (Hannover, Germany)

**Discussion and Q&A**

---

### Symposium: How much lung disease is really caused by work, and how to assess the worker who wishes to continue working?

**Statement of findings by the Official European Respiratory Society and the American Thoracic Society**

**Aims:** To describe the contribution of inhalational workplace hazards to the burden of nonmalignant lung diseases; to identify respiratory conditions with an estimated occupational burden 10%, including asthma, COPD, chronic bronchitis, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis, and other noninfectious granulomatous lung diseases (sarcoidosis, PAP, community acquired pneumonia); to describe the contribution of workplace exposure to various respiratory diseases and strategies that can improve the recognition and prevention of these diseases; and to evaluate various work, workplace and fitness considerations for patients with occupational lung diseases.

**Disease(s):** Airway diseases, Interstitial lung diseases, Respiratory infections

**Method(s):** Epidemiology, General respiratory patient care, Pulmonary function testing

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Physician in Pulmonary Training, Physiologist, Scientist (basic, translational)

**Chairs:** Charlotte Suppli Ulrik (Virum, Denmark), Andrew Bush (London, United Kingdom)

**11:50** Introduction

**11:55** COPD and bronchitis; how much is caused by work, and which occupations cause the most harm?

David Fishwick (Sheffield (South Yorkshire), United Kingdom)

**12:04** Wheeze and crackles: how much does the workplace contribute?

Isabella Annesi Maesano (Paris, France)

**12:13** Rare lung diseases and work: always bear occupation in mind when assessing these patients

Denis Vinnikov (Almaty, Kazakhstan)

**12:22** How important is work as a risk for lung infections? A story of tuberculosis and pneumonia

Nithiseelan Rajen Naidoo (Durban, South Africa)

**12:31** Work, workplace and fitness considerations in patients with occupational lung diseases

Christopher Barber (Sheffield (South Yorkshire), United Kingdom)

**12:40** Discussion and Q&A

---

### Studio Madrid

**Session 11:50 - 12:50**

Lungs on fire: Respiratory infections?

---

### Studio Vienna

**Session 11:50 - 12:50**

Lungs on fire: Respiratory infections?
**Aims:** To describe real-life clinical cases during the innovative interactive session, including the presentation of cases that have various levels of difficulty and often necessitate a differential diagnosis. This session will be led by a discussant, who will present the cases to a panel of experts and the audience. The discussant will encourage discussion among the panel of experts, who are encountering these cases for the first time. To further determine diagnostic and therapeutic options for these patients, the discussant will also invite audience participation in the reflection and discussion of these cases.

**Disease(s):** Respiratory infections

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Respiratory critical care physician, Clinical researcher, General practitioner, Paediatrician, Radiologist, Thoracic surgeon, Nurse, Respiratory physiotherapist

**Chairs:** Daiana Stolz (Basel, Switzerland), Omar S. Usmani (London, United Kingdom), Chair to be confirmed

**Discussants:** Michael Tamm (Basel, Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:50 | Introduction and presentation by the session discussant  
Michael Tamm (Basel, Switzerland) |
| 11:54 | Case 1                                      |
| 12:04 | Discussion and Q & A                       |
| 12:08 | Case 2                                      |
| 12:18 | Discussion and Q & A                       |
| 12:22 | Case 3                                      |
| 12:32 | Discussion and Q & A                       |
| 12:36 | Case 4                                      |
| 12:46 | Discussion and Q & A                       |

**Channel 1**

**Session** 11:50 - 12:50

**Primary care session: Part II: From symptoms to diagnosis in primary care**

**Aims:** To present how to choose the most effective diagnostic work up and management for common respiratory symptoms.

**Disease(s):** Airway diseases, Interstitial lung diseases, Paediatric respiratory diseases

**Tag(s):** Clinical

**Chairs:** Janwillem W. H. Kocks (Groningen, Netherlands), Chair to be confirmed

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50</td>
<td>Introduction</td>
</tr>
<tr>
<td>11:55</td>
<td>Respiratory care in different situations: an overview of the epidemiology of respiratory diseases and their (co)morbidity</td>
</tr>
</tbody>
</table>
| 12:05 | Pharmacotherapy in patients with multi-morbid COPD  
Ioanna Tsiligianni (Heraklion (Crete), Greece) |
| 12:15 | The blood (vessels) and the lung: what the general practitioner needs to know about circulation (a bit of heart) and the lungs  
Anton Vonk Noordegraaf (Amsterdam, Netherlands) |
| 12:35 | Methods of managing airway diseases in pregnancy  
Vibeke Backer (Copenhagen, Denmark) |
| 12:35 | Discussion and Q & A                       |

**Studio Paris**

**Session** 11:50 - 12:50

**State of the art session: Airway diseases**

**Is there a problem with...? Treatment approaches in asthma and COPD**

**Aims:** To evaluate the use of short-acting beta-2 agonist (SABA) monotherapy and oral corticosteroid (OCS) use in asthma; to describe concerns related to the use of inhaled corticosteroids (ICS) in COPD; and to determine the optimal inhalation device for patients with COPD.
Introduction

11:55  Is there a problem with short-acting beta-2 agonist monotherapy in asthma?  
David Price (Singapore, Singapore)

12:05  Is there a problem with oral corticosteroid use in asthma?  
Guy Brusselle (Ghent, Belgium)

12:15  Is there a problem with inhaled corticosteroid use in COPD?  
James D. Chalmers (Dundee (Angus), United Kingdom)

12:25  ERS Short Guideline: Inhaled corticosteroid withdrawal in COPD  
Marc Miravitlles (Barcelona (CT), Spain)

12:35  Discussion and Q & A

Challenging clinical cases: Pulmonary vascular diseases

Aims: To describe the history, pathology, analysis and treatment of complex clinical cases in respiratory critical care. The session leaders will facilitate discussions among the case presenters and audience.

14:30  Introduction

14:35  Case 1

14:41  Discussion and Q & A

14:46  Case 2

14:52  Discussion and Q & A

14:57  Case 3

15:03  Discussion and Q & A

15:08  Case 4

15:14  Discussion and Q & A

15:19  Case 5

15:25  Discussion and Q & A

Symposium: Fear and anxiety, psychological wellbeing and prevention of psychological distress in chronic lung diseases

Risk factors and novel treatment strategies

Aims: To identify fear and anxiety as important risk factors for poor treatment outcomes in asthma and COPD as well as differentiate between the role of fear versus anxiety; to explain the role of different behavioral treatment approaches in the treatment of asthma and COPD and explore the role of anxiety and fear in adaptive vs. non-adaptive trigger avoidance behaviors; to identify novel treatment approaches that focus on countering experiential and behavioral avoidance; to identify challenges to the implementation of behavioral health in asthma and COPD care and indicate how innovative treatment approaches (ehealth, mhealth, training respiratory nurses in cognitive behavioral therapy techniques) can help mitigate these challenges.
**Hot topics: (Re-)discovering the small airway epithelium in COVID-19, fibrosing lung diseases and pulmonary regeneration**

**Aims:** To summarize the clinical evidence for a pathogenic role of small airway cells in COVID-19 and fibrosing lung diseases; to explore the novel concept that small airways are central to the processes involved in regenerating and repairing a fibrosing lung. New developments regarding innovative in vitro models will allow us to exploit the regenerative and therapeutic potential of modulating small airway cells in lung fibrosis. **AIMS:** To highlight the contribution of small airway cells in COVID-19 and lung fibrosis from a clinical perspective; to understand the key role of small airways in lung regeneration and fibrosis; to demonstrate the regenerative potential of small airway cells and their likelihood as new therapeutic targets for pulmonary fibrosis; to explore novel models to study small airway cells and their regenerative capacities in pulmonary fibrosing diseases.

**Disease(s):** Airway diseases, Interstitial lung diseases

**Tag(s):** Basic science

**Target audience:** Clinical researcher, Medical Student, Pathologist, Scientist (basic, translational), Thoracic surgeon

**Chairs:** Anh Tuan Dinh-Xuan (Paris, France), Niki Ubags (Epalinges, Switzerland)

14:30 Introduction

14:35 The role of bronchial epithelial cells in COVID-19 infection and pathogenesis
Roland Eils (Heidelberg, Germany)

14:45 Airway basal cell involvement in idiopathic pulmonary fibrosis
Antje Prasse (Hannover, Germany)

14:55 Uncovering the plasticity of lung epithelial cells by scRNA sequencing
Herbert Schuller (Munich, Germany)

15:05 Modeling the regenerative potential of airway epithelial cells
Pieter S. Hiemstra (Leiden, Netherlands)

15:15 Discussion and Q & A
14:30 Introduction and presentation by the session facilitator
  Antoni Torres (Barcelona, Spain)

14:34 Case 1

14:44 Discussion and Q & A

14:48 Case 2

14:58 Discussion and Q & A

15:02 Case 3

15:12 Discussion and Q & A

15:16 Case 4

15:26 Discussion and Q & A

Channel 1 Session 14:30 - 15:30
Language session: French programme 2020: Part I
A joint ERS/SPLF session
Disease(s): Airway diseases, Interstitial lung diseases, Respiratory critical care
Tag(s): Clinical
Chairs: Bernard Maitre (Créteil Cedex, France), Marc Humbert (Le Kremlin-Bicêtre, France)

14:30 Introduction

14:35 Des lésions précancéreuses au cancer invasif / From precancerous lesions to invasive carcinoma
  Speaker to be confirmed

14:45 Troubles respiratoires du sommeil et cancer : données épidémiologiques / Respiratory disorders
  associated with sleep and cancer: epidemiological data
  Jean-Louis Pépin (Grenoble, France)

14:55 Tt anti fibrotiques hors FPI: approche raisonnée / Anti-fibrotic treatments for conditions other than
  idiopathic pulmonary fibrosis
  Vincent Cottin (Lyon, France)

15:05 Mucoviscidose: enfin des traitements ciblés / Cystic fibrosis: targeted therapies, at last!
  Pierre-Régis Burgel (Sorbonne Paris Cité, France)

15:15 Discussion and Q & A

Studio Paris Session 14:30 - 15:30
Guidelines session: The European Respiratory Society guidelines for the diagnosis of asthma in
children aged 5-16 years
Aims: To present the results from the ERS task force for the development of European Respiratory Society guidelines for the diagnosis of asthma in children aged 5-16 years. The background, motivation and methodology to produce such guidelines will be discussed. The core recommendations will be presented and underscored with some clinical cases. A commentary will present a view from outside the task force.
Disease(s): Paediatric respiratory diseases
Tag(s): Clinical
Target audience: Adult pulmonologist/ Clinician, General practitioner, Nurse, Paediatrician, Physician in Pulmonary Training
Chairs: Reinoud Gosens (Groningen, Netherlands), Marijke Proesmans (Leuven, Belgium)

14:30 Introduction

14:35 Why guidelines for Asthma Diagnosis in school children? Background and Motivation
  Erol Gaillard (Leicester (Leicestershire), United Kingdom)

14:45 How should Asthma be diagnosed in school children?: Recommendations of the evidence based ERS-
  Guidelines
  Alexander Möller (Zürich, Switzerland)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:55</td>
<td>New ERS-Guidelines for Asthma Diagnosis in school children: The view from outside the Task-force</td>
</tr>
<tr>
<td></td>
<td>Hilary Pinnock (Edinburgh (Edinburgh), United Kingdom)</td>
</tr>
<tr>
<td>15:05</td>
<td>How do the new Guidelines work: practical approach with cases and interactive questions</td>
</tr>
<tr>
<td></td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>15:15</td>
<td>Discussion and Q&amp;A</td>
</tr>
</tbody>
</table>

### Studio Paris Session 15:40 - 16:40

**Symposium: Reflections from the Lung Science 2020 conference**

**Aims:** The ERS Lung Science Conference is at the forefront of basic and translational respiratory science and it is an essential event for budding respiratory researchers looking to boost their career. It offers a unique opportunity to network with peers from across the globe and aims to present cutting-edge abstracts on novel experimental lung research. The Lung Science Conference 2020 took place on March 5-8 in Estoril, Portugal with the overarching theme metabolic alterations in lung ageing and disease. This session features a selection of scientific presentations that were given at this conference. In addition, the session highlights the winners of the William MacNee Award - for young presenters (40 years old or less at the time of the Conference) who submitted an outstanding abstract, and of the Geoffrey Laurent Award - for the Best Oral presentation.

**Disease(s):** Airway diseases, Interstitial lung diseases

**Tag(s):** Basic science

**Target audience:** Clinical researcher, Medical Student, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Scientist (basic, translational)

**Chairs:** Reinoud Gosens (Groningen, Netherlands), Marijke Proesmans (Leuven, Belgium)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Herbert Schiller (Munich, Germany)</td>
<td></td>
</tr>
<tr>
<td>15:54</td>
<td>The promise of mTOR signaling as a therapeutic target for IPF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rachel Chambers (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>16:03</td>
<td>Itaconate drives the resolution of pulmonary fibrosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patricia Ogger (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>16:12</td>
<td>Versatile workflow for storage, characterization and celltype resolved transcriptional and epigenetic profiling of human lung samples</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renata Jurkowska (Cardiff (Wales), United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>16:21</td>
<td>Mitochondrial iron in the susceptibility, pathogenesis and progression of COPD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suzanne Cloonan (New York City, United States of America)</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Discussion and Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### Studio Madrid Session 15:40 - 16:40

**Symposium: Air pollution and interstitial lung disease: a call to arms**

**Aims:** To describe the associations of air pollution with interstitial lung diseases (ILD) and pulmonary fibrosis (PF); to describe the importance of collective preventive measures to help patients breathe clean air and reduce their risks of ILD and progression to PF and death.

**Disease(s):** Interstitial lung diseases

**Method(s):** Epidemiology

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Respiratory therapist, Medical Student, Nurse, Physician in Pulmonary Training, Physiologist, Respiratory critical care physician, Respiratory physiotherapist, Journalist

**Chairs:** Anh Tuan Dinh-Xuan (Paris, France), Niki Ubags (Epalinges, Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>Genetic predisposition and the environment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maria Molina Molina (Barcelona, Spain)</td>
<td></td>
</tr>
<tr>
<td>15:54</td>
<td>Air pollution: particle size matters</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker to be confirmed</td>
<td></td>
</tr>
</tbody>
</table>
Symposium: Don't blame your parents: causes of pulmonary hypertension in early life

**Aims:** To present recent advances in gene discovery in pulmonary hypertension; to explain how these genes might provide new insights into the disease; to describe genetic screening in pulmonary hypertension; and to determine the biology and clinical characteristics of lung developmental disorders and their effects on the development of pulmonary hypertension.

**Disease(s):** Pulmonary vascular diseases

**Method(s):** Cell and molecular biology, Epidemiology, General respiratory patient care

**Tag(s):** Translational

**Target audience:** Adult pulmonologist/Clinician, Paediatrician, Patient, Radiologist, Scientist (basic, translational)

**Chairs:** Thierry Troosters (Leuven, Belgium), Marion Delcroix (Leuven, Belgium)

15:40 **Introduction**

15:45 **What do we learn from novel genes in pulmonary hypertension?**

Nicholas Morrell (Cambridge (Cambridgeshire), United Kingdom)

15:55 **Should we screen for hereditary pulmonary hypertension?**

David Montani (Le Kremlin-Bicêtre, France)

16:05 **Does gender matter in pulmonary hypertension?**

Anna Ryan Hemnes (Nashville, United States of America)

16:15 **Bronchopulmonary dysplasia as a cause of pulmonary hypertension**

Elianne J.L.E. Vrijlandt (Groningen, Netherlands)

16:25 **Discussion and Q & A**

---

Respiratory medicine meets other disciplines: Precision endotyping of asthma: time for action

**Aims:** To describe the precision endotyping of asthma and its co-morbidities by linking pathobiological mechanisms with visible properties via specific biomarkers translated into pathway-specific diagnostic tests; to evaluate how artificial intelligence complements standard diagnostic procedures in patients with allergic diseases and asthma; to determine how this approach enhances accurate asthma classification and individualised targeted treatments; and to describe dynamic complex endotypes consisting of several subendotypes and its validation.

**Disease(s):** Airway diseases

**Method(s):** Cell and molecular biology, Epidemiology, Physiology

**Tag(s):** Translational

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Nurse, Patient, Physiologist, Respiratory physiotherapist, Journalist, Scientist (basic, translational)

**Chairs:** Marek Jutel (Wroclaw, Poland), Antonio Spanevello (Milan, Italy)

15:40 **Introduction**

15:45 **Allergy testing and immunotherapy guidelines**

Ioana Agache (Brasov (Brasov), Romania)

15:55 **High-dimensional multivariable analysis of asthma and its co-morbidities**

Bianca Schaub (Germering, Germany)
16:05   **Upper airways in asthmatic patients**  
Apostolos Bossios (Stockholm, Sweden)

16:15   **Linking clinical algorithms to precision medicine**  
Matteo Bonini (Rome, Italy)

16:25   **Does the endotype-driven approach translate into improved quality of life?**  
Breda Flood (Gorey, Ireland)

16:30   **Discussion and Q & A**

---

**Studio Vienna**  
**Session**  
**Live from the clinic: Endoscopy and ultrasound**

**Chairs:** Maren Schuhmann (Heidelberg, Germany), Gilbert Massard (Esch Sur Alzette, Luxembourg), Chair to be confirmed

15:40   **Introduction**

---

**Studio Madrid**  
**Session**  
**Symposium: The ageing lung epithelium: effects on repair and regeneration**

**Aims:** To describe age-related impairments in lung repair and evaluate therapeutic strategies that target age-dependent dysfunction in lung disease; to describe the mechanism by which the ageing epithelium contributes to disease susceptibility; to evaluate current methods and models (in vitro and in vivo) for studying the activation of ageing pathways in acute and chronic lung diseases; to evaluate preclinical and clinical development of age-altering therapeutic strategies and scientific advances that may direct current and future therapeutic developments; and to determine the potential for developing new therapies, identifying biomarkers and differentiating among therapies designed to prevent and/or reverse ageing-associated pulmonary diseases.

**Disease(s):** Airway diseases, Interstitial lung diseases

**Method(s):** Cell and molecular biology, Imaging

**Tag(s):** Basic science

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Patient, Scientist (basic, translational), Thoracic surgeon

**Chairs:** Anh Tuan Dinh-Xuan (Paris, France), Niki Ubags (Epalinges, Switzerland)

16:50   **Introduction**

16:55   **Targeting the lung epithelium: does age matter?**  
Paul Wolters (San Francisco, United States of America)

17:05   **Senescence and immune ageing**  
Mauricio Rojas (Pittsburgh, United States of America)

17:15   **Cellular senescence in regeneration and diseases of the lung**  
Mareike Lehmann (München, Germany)

17:25   **The inflammatory niche of the aged lung**  
Speaker to be confirmed

17:35   **Discussion and Q & A**

---

**Studio Paris**  
**Session**  
**Hot topics: Bugs secret's: the way the microbiome changes our future**

**Aims:** To summarize what is currently known on the microbiome and its influence on health and disease with special attention to lung diseases, from infancy, priming into malfunction of the microbiome in diseases such as allergic diseases, asthma, cystic fibrosis (CF) and later into COPD exacerbations; to highlight studies of early colonisation and microbiome formation into assessing possible intervention strategies to reach a healthy balance of microbial colonization, also important for allergy prevention; to take a critical view on current treatment strategies and stressing the influence of microbial dysbiosis as a feature of some exacerbations in chronic airway diseases such as asthma, CF and COPD.

**Disease(s):** Airway diseases, Paediatric respiratory diseases, Respiratory infections

**Tag(s):** Translational

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Respiratory critical care physician, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational), Respiratory therapist, Journalist

**Chairs:** Reinoud Gosens (Groningen, Netherlands), Marijke Proesmans (Leuven, Belgium)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 16:55 | Understanding new measurement techniques of the microbiome of the lung and mechanism of bacteria interaction, communication and biofilm formation  
Speaker to be confirmed |
| 17:05 | Early life microbiome: the way it changes the future  
Speaker to be confirmed |
| 17:15 | Bacterial dysbiosis in pediatric lung diseases such as asthma and CF  
Alexander Dalpke (Dresden, Germany) |
| 17:25 | Lung microbial factors as drivers for COPD  
Speaker to be confirmed |
| 17:35 | Discussion and Q&A                                                     |

### Channel 1

**Session 16:50 - 19:00**

**Language session: German programme 2020**

A joint ERS/DGP/SGP/OGP session

**Chairs:** Sylvia Hartl (Wien, Austria), Otto Chris Burghuber (Wien, Austria), Thomas Geiser (Bern, Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 16:55 | ICS discontinuation guidelines in COPD  
Daiana Stolz (Basel, Switzerland) |
| 17:10 | Severe asthma guidelines: 2019 update  
Roland Buhl (Mainz, Germany) |
| 17:25 | Discussion and Q&A                                                     |
| 17:35 | New guidelines for treatment of nontuberculous mycobacterial pulmonary disease  
Felix C. Ringshausen (Hannover, Germany) |
| 17:50 | Management of severe community acquired pneumonia  
Tobias Welte (Hannover, Germany) |
| 18:05 | Discussion and Q&A                                                     |
| 18:15 | Sarcoidosis  
Francesco Bonella (Düsseldorf, Germany) |
| 18:30 | Guidelines for long-term non-invasive ventilation in patients with COPD  
Wolfram Windisch (Cologne, Germany) |
| 18:45 | Discussion and Q&A                                                     |

### Studio Milan

**Session 16:50 - 17:50**

**State of the art session: Pulmonary vascular diseases**

**Treatment and prevention of severe pulmonary hypertension**

**Aims:** To describe current therapeutic approaches in pulmonary hypertension and to evaluate whether better knowledge of the side effects of drugs can enhance disease prevention.

**Disease(s):** Pulmonary vascular diseases

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Scientist (basic, translational)

**Chairs:** Thierry Troosters (Leuven, Belgium), Marion Delcroix (Leuven, Belgium)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50</td>
<td>Introduction</td>
</tr>
</tbody>
</table>
| 16:55 | Drug-related pulmonary hypertension: new threats?  
David Montani (Le Kremlin-Bicêtre, France) |
| 17:05 | PROs: which instruments are available in pulmonary hypertension?  
Joanna Pepke-Zaba (Cambridge (Cambridgeshire), United Kingdom) |
Studio Milan Session 18:00 - 19:00
Symposium: Cardiovascular morbidity and mortality after pulmonary embolism

**Aims:** To describe the long-term cardiovascular morbidity and mortality after acute pulmonary embolism; to summarize relevant information about acute pulmonary embolism in association with certain specific cardiopulmonary conditions.

**Disease(s):** Pulmonary vascular diseases

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Patient

**Chairs:** Thierry Troosters (Leuven, Belgium), Marion Delcroix (Leuven, Belgium)

18:00 Introduction

18:05 Atrial fibrillation in the course of pulmonary embolism: just a little smoke or fuel to the fire?  
Behnood Bikdeli (New York, United States of America)

18:15 Management of pulmonary embolism beyond the acute phase: pay attention to long-term sequelae  
Irene Lang (Wien, Austria)

18:25 Venous thromboembolism and arterial atherosclerosis: a bidirectional association  
Speaker to be confirmed

18:35 Closing the gap between pulmonary embolism and sleep apnea  
Alberto Garcia Ortega (Valencia, Spain)

18:45 Discussion and Q & A

Studio Paris Session 18:00 - 19:00
Symposium: Human ex vivo models of interstitial lung disease

**Aims:** To present models of early events of idiopathic pulmonary fibrosis (IPF) ex vivo and the use of these models in evaluating pathogenesis and treatment; and to evaluate the potential use of lung organoids for drug screening.

**Disease(s):** Interstitial lung diseases

**Method(s):** Cell and molecular biology

**Tag(s):** Basic science

**Target audience:** Adult pulmonologist/ Clinician, Clinical researcher, Medical Student, Physician in Pulmonary Training, Scientist (basic, translational)

**Chairs:** Reinoud Gosens (Groningen, Netherlands), Marijke Proesmans (Leuven, Belgium)

18:00 Introduction

18:05 3D tissue culture to study the mechanisms of lung repair in IPF  
Melanie Königshoff (Denver, United States of America)

18:15 Using induced pluripotent stem cells to study the type II pneumocyte  
Killian Hurley (Dublin 3, Ireland)

18:25 Lung-on-a-chip: state of the art  
Nina Hobi (Bern, Switzerland)

18:35 The role of cell lines in modelling the type II pneumocyte in interstitial lung disease  
Jennifer Dickens (Cambridge (Cambridgeshire), United Kingdom)

18:45 Discussion and Q & A
Journal session: When the lung gets stiff
Diagnosis, treatment and controversy (a joint ERS/New England Journal of Medicine (NEJM) session)

**Aims:** To describe the pathobiology, epidemiology, causes, diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), the most common type of interstitial lung disease; to evaluate pulmonary fibrosis resulting from other diagnosable conditions, such as scleroderma, sarcoidosis and rheumatoid arthritis; to describe the epidemiology, biology, clinical presentation and treatment of this group of conditions; and to describe controversies in the diagnosis and treatment of rapidly progressive-interstitial lung diseases.

**Disease(s):** Interstitial lung diseases

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Patient, Physician in Pulmonary Training, Scientist (basic, translational)

**Chairs:** Anh Tuan Dinh-Xuan (Paris, France), Niki Ubags (Epalinges, Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td>Introduction</td>
<td>Jeffrey Drazen (Boston, United States of America)</td>
</tr>
<tr>
<td>18:05</td>
<td>Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment</td>
<td>Fernando J. Martinez (New York, United States of America)</td>
</tr>
<tr>
<td>18:15</td>
<td>Interstitial lung diseases (ILDs) secondary to other conditions: common biology, epidemiology, diagnosis and treatment</td>
<td>Marlies S. Wijsenbeek (Rotterdam, Netherlands)</td>
</tr>
<tr>
<td>18:25</td>
<td>Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity?</td>
<td>Elisabetta Renzoni (London, United Kingdom), Vincent Cottin (Lyon, France)</td>
</tr>
<tr>
<td>18:45</td>
<td>Discussion and Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>18:55</td>
<td>Conclusion</td>
<td>Jeffrey Drazen (Boston, United States of America)</td>
</tr>
</tbody>
</table>
### Studio Madrid  Session  09:30 - 10:30

**Symposium: Early career member: activities, opportunities and motivations**

**Early career member session 2020**

**Aims:** To evaluate the structure of and opportunities provided by the ERS; to describe methods of active involvement in the ERS; to present current fellowship offers from the ERS; and to describe critical steps for a successful future career in respiratory research and medicine.

**Target audience:** Clinical researcher, Medical Student

**Chairs:** Carlos Robalo Cordeiro (Coimbra, Portugal), Niki Ubags (Epalinges, Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:35</td>
<td><strong>ERS: structure, activities, opportunities:</strong> view of the Early Career Members Committee (ECMC)**&lt;br&gt;Maxime Patout (Mont-Saint Aignan, France)</td>
</tr>
<tr>
<td>09:45</td>
<td><strong>ERS fellowship: an overview:</strong> experience of a Respire3 fellow&lt;br&gt;Louise Donnelly (London, United Kingdom)</td>
</tr>
<tr>
<td>09:55</td>
<td><strong>Mina Gaga lecture</strong>&lt;br&gt;Daniela Gompelmann (Heidelberg, Germany)</td>
</tr>
<tr>
<td>10:05</td>
<td><strong>Motivation and leadership in science</strong>&lt;br&gt;Daniela Gompelmann (Heidelberg, Germany)</td>
</tr>
<tr>
<td>10:15</td>
<td><strong>Discussion and Q &amp; A</strong></td>
</tr>
</tbody>
</table>

### Studio Vienna  Session  09:30 - 11:40

**Grand round: Paediatric grand round**

**Aims:** To describe children with challenging respiratory diseases, including their differential diagnosis, diagnostic tests and optimal clinical care; and to present an update on selected topics in paediatric respiratory medicine.

**Disease(s):** Paediatric respiratory diseases

**Tag(s):** Clinical

**Target audience:** Clinical researcher, Medical Student, Nurse, Paediatrician, Physician in Pulmonary Training, Radiologist

**Chairs:** Ernst Eber (Graz, Austria), Monika Gappa (Düsseldorf, Germany), Andrew Bush (London, United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:35</td>
<td><strong>A 2-year-old girl with recurrent wheeze</strong>&lt;br&gt;Megan Frohlich (Narara (NSW), Australia)</td>
</tr>
<tr>
<td>09:55</td>
<td><strong>Discussion and Q &amp; A</strong>&lt;br&gt;Megan Frohlich (Narara (NSW), Australia)</td>
</tr>
<tr>
<td>10:05</td>
<td><strong>CHILD: Childhood improbable late diagnoses?</strong>&lt;br&gt;Sormeh Salehian (London, United Kingdom)</td>
</tr>
<tr>
<td>10:25</td>
<td><strong>Discussion and Q &amp; A</strong>&lt;br&gt;Sormeh Salehian (London, United Kingdom)</td>
</tr>
<tr>
<td>10:35</td>
<td><strong>What is taking my breath away? A medical detective story</strong>&lt;br&gt;Speaker to be confirmed</td>
</tr>
<tr>
<td>10:55</td>
<td><strong>Discussion and Q &amp; A</strong>&lt;br&gt;Speaker to be confirmed</td>
</tr>
<tr>
<td>11:05</td>
<td><strong>Persistent lung consolidations in a 9-year-old</strong>&lt;br&gt;Laura Petrarca (Roma (RM), Italy)</td>
</tr>
<tr>
<td>11:25</td>
<td><strong>Discussion and Q &amp; A</strong>&lt;br&gt;Laura Petrarca (Roma (RM), Italy)</td>
</tr>
</tbody>
</table>

### Studio Paris  Session  09:30 - 10:30

**Hot topics: Insights from wearable respiratory sensors and AI**
**Aims:** To present opportunities opened by wearable monitoring of ambulant and (semi-)continuous monitoring, leading to large data streams; to understand these rapidly expanded fields over recent years; to highlight the opportunities and show promising results, e.g. in the fields of sleep apnea and rehabilitation; to emphasize challenges with respect to reliability and interpretability of the results in clinical practice; to describe the current developments around wearable devices and AI and to discuss the opportunities and open challenges; to facilitate exchange and dialogue around these developments in the domain of digital health. To understand how the COVID-19 epidemic is developing, who is at most risk, what is the effect of social distancing, and when and where providers can expect people to require healthcare services.

**Disease(s):** [Airway diseases](#) [Sleep and breathing disorders](#)  
**Tag(s):** Basic science

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Patient, Physiologist, Scientist (basic, translational)

**Chairs:** Richard Costello (Dublin 9, Ireland), Hilary Pinnock (Edinburgh (Edinburgh), United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>09:35</td>
<td>AI for respiratory signals</td>
<td>Tom Van Steenkiste (Ghent, Belgium)</td>
</tr>
<tr>
<td>09:45</td>
<td>Health patches for wearable respiration monitoring</td>
<td>Bernard Grundlehner (Eindhoven, Netherlands)</td>
</tr>
<tr>
<td>09:55</td>
<td>Respiration monitoring in COPD patients</td>
<td>Dolores Blanco-Almazán (Barcelona, Spain)</td>
</tr>
<tr>
<td>10:05</td>
<td>Diagnosis of COVID-19 with a radar app</td>
<td>Niels H. Chavannes (Leiden, Netherlands)</td>
</tr>
<tr>
<td>10:15</td>
<td>Discussion and Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### Channel 1 Session 09:30 - 10:30

**Language session: French programme 2020: Part II**  
A joint ERS/SPLF session

**Disease(s):** [Airway diseases](#) [Interstitial lung diseases](#) [Respiratory critical care](#)  
**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician

**Chairs:** Thierry Troosters (Leuven, Belgium), Chantal Raherison-Semjen (Pessac, France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>09:35</td>
<td>Diagnostic de l’EP chez la femme enceinte / Diagnosis of pulmonary embolism in pregnant women</td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>09:45</td>
<td>Place des anti-IL 5 dans les pathologies éosinophiliques hors asthme sévère / Anti-IL-5 therapy for indications other than severe asthma</td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>09:55</td>
<td>Risques cardiovasculaires et BPCO / Cardiovascular risks and COPD</td>
<td>Bruno Degano (grenoble, France)</td>
</tr>
<tr>
<td>10:05</td>
<td>Exploration de la fonction respiratoire selon l’âge / Lung function testing and age</td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>10:15</td>
<td>Discussion and Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### Studio Milan Session 09:30 - 10:30

**State of the art session: Thoracic oncology**

**Aims:** To describe current methods of managing lung cancer and other intrathoracic tumours based on the latest developments in imaging, pathology and molecular biology.

**Disease(s):** [Thoracic oncology](#)  
**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Pathologist, Physician in Pulmonary Training, Radiologist, Thoracic oncologist, Thoracic surgeon
President: Mina Gaga (Athens, Greece), Chair to be confirmed

09:30 Introduction

09:35 Implementation of lung cancer screening in Europe: the way forward
Emma O’Dowd (Nottingham, United Kingdom)

09:45 Perioperative systemic therapy in resectable lung cancer: from standard operating procedures to immuno-oncology and back
Isabelle Opitz (Zurich, Switzerland)

09:55 Radiotherapy in small cell lung cancer: patient options
Speaker to be confirmed

10:05 Update on supportive care
Speaker to be confirmed

10:15 Discussion and Q&A

Studio Madrid

Session 10:40 - 11:40
Hot topics: Interstitial lung disease patients in the intensive care unit

Aims: To discuss: 1.) the different phenotypes of interstitial lung diseases (ILD) patients in the intensive care unit (ICU); 2) the importance of appropriate patient selection in determining outcome; 3) the potential prognostic role of computerized tomography (CT) and bronchoalveolar lavage (BAL)/biopsy; 4) the role of extracorporeal membrane oxygenation (ECMO) as bridge to recovery and transplantation; 5) treatment strategies and algorithms

Disease(s): Interstitial lung diseases, Respiratory critical care

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Respiratory critical care physician, Pathologist, Radiologist

Chairs: Carlos Robalo Cordeiro (Coimbra, Portugal), Niki Ubags (Epalinges, Switzerland)

10:40 Introduction

10:45 Selection of ILD patients for ICU and ECMO
Cara Agerstrand (New York, United States of America)

10:55 Radiological patterns in ICU: does it matter?
Nicola Sverzellati (Parma (PR), Italy)

11:05 Diagnostic procedures in ICU: bronchoscopy and BAL or tissue?
Claudia Ravaglia (Forlì, Italy)

11:15 Management of ILD patients in ICU
Maria Kokosi (London, United Kingdom)

11:25 Discussion and Q&A

Studio Milan

Session 10:40 - 12:50
Live from the clinic: Physiology

Chairs: Mina Gaga (Athens, Greece), Chair to be confirmed

10:40 Introduction

Channel 4

Session 11:50 - 12:50
Challenging clinical cases: Thoracic oncology

Aims: To describe the history, pathology, analysis and treatment of complex clinical cases in respiratory critical care. The session leaders will facilitate discussions among the case presenters and audience.

Disease(s): Thoracic oncology

Tag(s): Clinical

Target audience: Thoracic oncologist, Thoracic surgeon, Respiratory critical care physician, Adult pulmonologist/Clinician, General practitioner, Paediatrician, Pathologist, Nurse, Radiologist, Clinical researcher

Chairs: Torsten Gerriet Blum (Berlin, Germany), Georgia Hardavella (Athens, Greece)
**Studio Paris**

**Session**

**11:50 - 12:50**

**Symposium: Digital health: a brave new world?**

**Aims:** To provide clinicians with the patient perspective on the utility of sensors, trackers and monitors; to describe the role of digital technologies in tele-monitoring of asthma patients and the ability to predict asthma exacerbations; to describe recent advances in open platforms for patients and the importance of using connected e-Health to help patients with respiratory diseases live with their conditions; to describe the need to develop digital resources that are accessible and overcome problems of health literacy; and to assess the clinical ability of e-health technologies to help patients manage their pulmonary disorders and the promising role of artificial intelligence in future digital trials.

**Disease(s):** Airway diseases, Respiratory infections, Sleep and breathing disorders

**Method(s):** Public health, Pulmonary function testing, Pulmonary rehabilitation

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Respiratory therapist, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory critical care physician, Respiratory physiotherapist, Journalist, Scientist (basic, translational), Thoracic oncologist, Thoracic surgeon

**Chairs:** Richard Costello (Dublin 9, Ireland), Hilary Pinnock (Edinburgh (Edinburgh), United Kingdom)

**11:50 Introduction**

**11:55** Let’s start with the end-user, patients and digital: will they work together?
Dominique Hamerlijnck (Amsterdam, Netherlands)

**12:00** Combining digital technologies to monitor asthma control and predict asthma exacerbations
Omar S. Usmani (London, United Kingdom)

**12:10** New horizons in digital technologies for respiratory medicine
Vitalii Poberezhets (Vinnytsia, Ukraine)

**12:20** Designs of future digital trials and the promise of artificial intelligence
Konstantinos Kostikas (Ioannina, Greece)

**12:30** Connected health and eHealth literacy
Lars Kayser (Copenhagen, Denmark)

**12:40 Discussion and Q & A**

---

**Studio Vienna**

**Session**

**11:50 - 12:50**

**Lungs on fire: Paediatric respiratory diseases**

**Aims:** To describe real-life clinical cases during the innovative interactive session, including the presentation of cases that have various levels of difficulty and often necessitate a differential diagnosis. This session will be led by a discussant, who will present the cases to a panel of experts and the audience. The discussant will encourage discussion among the panel of experts, who are encountering these cases for the first time. To further determine diagnostic and therapeutic options for these patients, the discussant will also invite audience participation in the reflexion and discussion of these cases.

**11:50 Introduction**

**11:55** Let’s start with the end-user, patients and digital: will they work together?
Dominique Hamerlijnck (Amsterdam, Netherlands)

**12:00** Combining digital technologies to monitor asthma control and predict asthma exacerbations
Omar S. Usmani (London, United Kingdom)

**12:10** New horizons in digital technologies for respiratory medicine
Vitalii Poberezhets (Vinnytsia, Ukraine)

**12:20** Designs of future digital trials and the promise of artificial intelligence
Konstantinos Kostikas (Ioannina, Greece)

**12:30** Connected health and eHealth literacy
Lars Kayser (Copenhagen, Denmark)

**12:40 Discussion and Q & A**
State of the art session: Interstitial lung diseases (ILD) and beyond

**Aims**: Several task forces and position-statement papers are approved, submitted or ongoing in our Assembly 12. This session is going to discuss the major developments in the field through an update of the current TFs. Moreover, a collaboration with ATS of WASOG is ongoing for some of them. It would be exciting to have presented all together in a session with top quality speakers from Europe and beyond. The following projects will be discussed: 1. Diagnosis and treatment of hypersensitivity pneumonitis remain a real challenge; this talk-TF provides an overview of our current understanding and points out new opportunities for further research. 2. Genetics in ILDs: There is a growing body of evidence that both common and rare genetic variants contribute to the development and clinical manifestation of many of the ILDs. Here, we review the current understanding of genetic risk and ILD. 3. Sarcoidosis: or IPF and Lung Cancer; in preparation of a Consensus Statement; the results of the ERS Survey (speakers: Dan Culver or Carlo Vancheri) : in case that Sarcoidosis Diagnostic Guidelines and Treatment TF are presented in a separate section 4. Interventional Pulmonology and ILDs.

**Disease(s)**: Interstitial lung diseases, Pulmonary vascular diseases, Thoracic oncology

**Tag(s)**: Clinical

**Target audience**: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Nurse, Patient, Radiologist, Thoracic oncologist, Respiratory therapist, Journalist, Thoracic surgeon

**Chairs**: Carlos Robalo Cordeiro (Coimbra, Portugal), Niki Ubags (Epalinges, Switzerland)

**Introduction**: Jürg Hammer (Basel, Switzerland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50</td>
<td><strong>Introduction and presentation by the session facilitator</strong></td>
</tr>
<tr>
<td></td>
<td>Jürg Hammer (Basel, Switzerland)</td>
</tr>
<tr>
<td>11:54</td>
<td><strong>Case 1</strong></td>
</tr>
<tr>
<td>12:04</td>
<td><strong>Discussion and Q &amp; A</strong></td>
</tr>
<tr>
<td>12:08</td>
<td><strong>Case 2</strong></td>
</tr>
<tr>
<td>12:18</td>
<td><strong>Discussion and Q &amp; A</strong></td>
</tr>
<tr>
<td>12:22</td>
<td><strong>Case 3</strong></td>
</tr>
<tr>
<td>12:32</td>
<td><strong>Discussion and Q &amp; A</strong></td>
</tr>
<tr>
<td>12:36</td>
<td><strong>Case 4</strong></td>
</tr>
<tr>
<td>12:46</td>
<td><strong>Discussion and Q &amp; A</strong></td>
</tr>
</tbody>
</table>

**Pro/Con debate: Lung cancer screening: is it ready for implementation?**

**Chairs**: Joanna Chorostowska-Wynimko (Warsaw, Poland), Otto Chris Burghuber (Wien, Austria), Gilbert Massard (Esch Sur Alzette, Luxembourg)
14:20  Yes
Hans-Ulrich Kauczor (Heidelberg, Germany)

14:30  No
Speaker to be confirmed

14:40  Discussion
Hans-Ulrich Kauczor (Heidelberg, Germany), Speaker to be confirmed

Channel 4  Session  14:30 - 15:30

Challenging clinical cases: Airway diseases

Aims: To describe the history, pathology, analysis and treatment of complex clinical cases in respiratory critical care. The session leaders will facilitate discussions among the case presenters and audience.

Disease(s): Airway diseases

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, General practitioner, Clinical researcher, Respiratory critical care physician, Paediatrician, Respiratory physiotherapist, Radiologist

Chairs: Marco Idzko (Wien, Austria), Lena Uller (Lund, Sweden)

14:30  Introduction

14:35  Case 1

14:41  Discussion and Q & A

14:46  Case 2

14:52  Discussion and Q & A

14:57  Case 3

15:03  Discussion and Q & A

15:08  Case 4

15:14  Discussion and Q & A

15:19  Case 5

15:25  Discussion and Q & A

Studio Milan  Session  14:30 - 15:30

Symposium: Does exposure long before conception influence future respiratory health?

Aims: To describe the effects of exposures, lifestyles and behaviours before conception and in previous generations on asthma and respiratory health, including through multigenerational studies in humans and animals, epigenetic mechanistic research, and understanding susceptible stages during germ cell development.

Disease(s): Airway diseases, Paediatric respiratory diseases

Tag(s): Translational

Target audience: Adult pulmonologist/Clinician, General practitioner, Respiratory therapist, Medical Student, Paediatrician, Scientist (basic, translational)

Chairs: Sofia Belo Ravara (Covilhã, Portugal), Jørgen Vestbo (Manchester (Greater Manchester), United Kingdom)

14:30  Introduction

14:35  Before the beginning of life: how exposures of fathers and mothers before conception influence respiratory health in their children
Cecilie Svanes (Bergen, Norway)

14:45  Inter- and trans-generational effects in respiratory disease: epigenetic mechanisms
John Holloway (Southampton (Hampshire), United Kingdom)

14:55  Multigenerational animal models investigating the effects of exposures across generations.
Susanne Krauss-Etschmann (Borstel, Germany)
### Symposium Madrid Session 14:30 - 15:30

Symposium: Noninvasive respiratory assistance for acute respiratory failure outside the intensive care unit: a bargain or a burden?

**Aims:** To describe the advantages and disadvantages of noninvasive respiratory assistance, noninvasive ventilation (NIV) and/or high-flow nasal cannula (HFNC), to patients with acute respiratory failure outside the intensive care unit.

**Disease(s):** Respiratory critical care

**Method(s):** Respiratory intensive care

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Nurse, Physician in Pulmonary Training, Respiratory critical care physician, Respiratory physiotherapist, Journalist

**Chairs:** Anita Simonds (London, United Kingdom), Thierry Troosters (Leuven, Belgium)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>14:35</td>
<td>How to stratify the risk of failure of noninvasive respiratory assistance</td>
<td>Begüm Ergan (Izmir, Turkey)</td>
</tr>
<tr>
<td>14:45</td>
<td>Indications and pitfalls of high-flow nasal cannula (HFNC) outside the intensive care unit</td>
<td>Mark W. Elliott (Leeds (West Yorkshire), United Kingdom)</td>
</tr>
<tr>
<td>14:55</td>
<td>Remote monitoring devices: one more point for noninvasive assistance in the wards</td>
<td>Marieke L. Duiverman (Groningen, Netherlands)</td>
</tr>
<tr>
<td>15:05</td>
<td>Noninvasive respiratory assistance in respiratory high dependency units: a bargain for high risk patients?</td>
<td>Lara Pisani (Bologna (BO), Italy)</td>
</tr>
<tr>
<td>15:15</td>
<td>Discussion and Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### Channel 1 Session 14:30 - 15:30

Language session: Russian programme 2020: Part I Chronic obstructive pulmonary disease (a joint ERS/RRS/ARSRM session)

**Aims:** To provide up-to-date information about COPD, including its epidemiology, pathophysiology, diagnosis, clinical course, treatment and rehabilitation.

**Disease(s):** Airway diseases

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, General practitioner, Medical Student, Physician in Pulmonary Training, Radiologist, Respiratory physiotherapist, Journalist

**Chairs:** Kai Michael Beeh (Wiesbaden, Germany), Alexander G. Chuchalin (Moscow, Russian Federation)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>14:35</td>
<td>Pathomorphology of COPD</td>
<td>Maria Samsonova (Moscow, Russian Federation)</td>
</tr>
<tr>
<td>14:45</td>
<td>Classification of COPD: problems and controversies</td>
<td>Konstantinos Kostikas (Ioannina, Greece)</td>
</tr>
<tr>
<td>14:55</td>
<td>Pulmonary functional diagnosis of COPD</td>
<td>Zaurbek Aisanov (Moscow, Russian Federation)</td>
</tr>
<tr>
<td>15:05</td>
<td>Control of COPD</td>
<td>Marc Miravitlles (Barcelona (CT), Spain)</td>
</tr>
<tr>
<td>15:15</td>
<td>Discussion and Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Studio Paris  
State of the art session: Respiratory infections  
Big data in clinical practice  
**Aims:** To provide updates on clinically important aspects of respiratory infections; and to demonstrate how big data affect current clinical practice.  
**Disease(s):** Respiratory infections  
**Tag(s):** Clinical  
**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Respiratory critical care physician, Paediatrician, Patient, Physician in Pulmonary Training, Scientist (basic, translational)  
**Chairs:** Eva Polverino (Barcelona, Spain), Tobias Welte (Hannover, Germany)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:35</td>
<td>Pneumonia: strain type, vaccination and antibiotic resistance</td>
<td>Speaker to be confirmed</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>The lung microbiome and its effects on respiratory infections</td>
<td>Leopoldo N. Segal (New York New York, NY, United States of America)</td>
<td></td>
</tr>
<tr>
<td>14:55</td>
<td>Individualising treatment for tuberculosis: what has whole genome sequencing taught us so far?</td>
<td>Daniela Maria Cirillo (Milano (MI), Italy)</td>
<td></td>
</tr>
<tr>
<td>15:05</td>
<td>The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications</td>
<td>Felix Ratjen (Toronto (ON), Canada)</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>Discussion and Q &amp; A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Studio Vienna  
Pro/Con debate: Do I need a robot in my thoracic surgery operating theatre?  
**Aims:** To compare robotic surgery and video-assisted surgery for the treatment of chest malignancies such as lung cancer and mediastinal neoplasms; to provide an update on current application of robotic-assisted surgery and a thorough analysis of results in terms of preoperative evaluation and selection of patients, surgical outcome, postoperative length of stay, complication rate, general costs, learning curve, compared to the video-assisted thoracic surgery (VATS).  
**Disease(s):** Respiratory critical care, Thoracic oncology  
**Tag(s):** Clinical  
**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Respiratory critical care physician, Radiologist, Respiratory physiotherapist, Thoracic oncologist, Thoracic surgeon  
**Chairs:** Joanna Chorostowska-Wynimko (Warsaw, Poland), Otto Chris Burghuber (Wien, Austria), Gilbert Massard (Esch Sur Alzette, Luxembourg)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Yes</td>
<td>Speaker to be confirmed</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>No</td>
<td>Speaker to be confirmed</td>
<td></td>
</tr>
<tr>
<td>15:20</td>
<td>Discussion</td>
<td>Speaker to be confirmed</td>
<td></td>
</tr>
</tbody>
</table>

Studio Milan  
Symposium: Improving the delivery of tobacco-use treatment  
Successful stories in European and non-European countries  
**Aims:** To present a comprehensive overview on methods to effectively implement innovative tobacco cessation in healthcare; and to describe effective interventions for integrating tobacco cessation into health systems, including 1) health system engagement and organisational change; 2) use of healthcare providers’ reminder systems, electronic medical records and other information technology tools; 3) delivery of smoking cessation training to healthcare providers; and 4) patient involvement and health education.  
**Disease(s):** Airway diseases, Respiratory infections, Thoracic oncology  
**Tag(s):** Clinical  
**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Respiratory therapist, Medical Student, Medical Technical Assistant, Nurse, Paediatrician, Patient, Physician in Pulmonary Training, Respiratory physiotherapist, Journalist, Thoracic oncologist, Thoracic surgeon  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40</td>
<td>Symposium: Improving the delivery of tobacco-use treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>Successful stories in European and non-European countries</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Symposium: Community acquired pneumonia – new guidelines, major advances?

**Aims:** To appraise the recommendations of the new CAP guidelines and revisit important advances and drawbacks of the new recommendations to clinical care; to evaluate established and emerging evidence on complementary diagnostic methods in patients with suspicion of CAP; to revise the management of immunocompromised patients with suspicion of CAP; to discuss alternative diagnosis and management in non-resolving CAP and associated pleural infection.

**Disease(s):** Interstitial lung diseases, Respiratory critical care

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Nurse, Physician in Pulmonary Training, Physiologist

**Chairs:** Eva Polverino (Barcelona, Spain), Tobias Welte (Hannover, Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40</td>
<td>Introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>CAP guidelines 2019 - new and better?</td>
<td>Stefano Aliberti (Milano (MI), Italy)</td>
<td></td>
</tr>
<tr>
<td>15:55</td>
<td>Diagnosing CAP – any advances?</td>
<td>Cristina Prat Aymerich (Badalona (Barcelona), Spain)</td>
<td></td>
</tr>
<tr>
<td>16:05</td>
<td>CAP in the immunocompromised - more common than you think</td>
<td>Julio Ramirez (Louisville, United States of America)</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Non-resolving CAP - what to do when antibiotics do not help</td>
<td>Michael Tamm (Basel, Switzerland)</td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>Discussion and Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Grand round: Lung cancer grand round

**Aims:** To describe different aspects in the diagnosis and management of intrathoracic tumours, based on challenging clinical cases.

**Disease(s):** Thoracic oncology

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Medical Student, Pathologist, Physician in Pulmonary Training, Radiologist, Thoracic oncologist, Thoracic surgeon

**Chairs:** Joanna Chorostowska-Wynimko (Warsaw, Poland), Otto Chris Burghuber (Wien, Austria), Gilbert Massard (Esch Sur Alzette, Luxembourg)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40</td>
<td>Introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>A patient with a lazarus effect on tyrosine kinase inhibition</td>
<td>Dragana M. Jovanović (Beograd, Republic of Serbia)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>16:05</td>
<td>Discussion and Q &amp; A</td>
<td>Dragana M. Jovanović (Beograd, Republic of Serbia)</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Advanced non small cell lung cancer: an approach fit for the twenties</td>
<td>Wouter H. van Geffen (Leeuwarden, Netherlands)</td>
<td></td>
</tr>
<tr>
<td>16:35</td>
<td>Discussion and Q &amp; A</td>
<td>Wouter H. van Geffen (Leeuwarden, Netherlands)</td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td>A rare case of oligometastatic disease</td>
<td>Georgia Hardavella (Athens, Greece)</td>
<td></td>
</tr>
<tr>
<td>17:05</td>
<td>Discussion and Q &amp; A</td>
<td>Georgia Hardavella (Athens, Greece)</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>Adenoid cystic carcinoma of the trachea: not so benign</td>
<td>Jo Raskin (Kessel-Lo, Belgium)</td>
<td></td>
</tr>
<tr>
<td>17:35</td>
<td>Discussion and Q &amp; A</td>
<td>Jo Raskin (Kessel-Lo, Belgium)</td>
<td></td>
</tr>
</tbody>
</table>

### Channel 1 Session 15:40 - 16:40

**Language session: Russian programme 2020: Part II**

**Chronic obstructive pulmonary disease (a joint ERS/RRS/ARSRM session)**

**Aims:** To describe new findings about COPD, including its epidemiology, pathophysiology, diagnosis, clinical course, treatment and rehabilitation.

**Disease(s):** Airway diseases

**Tag(s):** Clinical

**Chairs:** David M. G. Halpin (Exeter, United Kingdom), Andrey Belevskiy (Moscow, Russian Federation)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>Clinical diagnosis of COPD</td>
<td>Sergey Avdeev (Moscow, Russian Federation)</td>
</tr>
<tr>
<td>15:55</td>
<td>Imaging of COPD</td>
<td>Igor Tyurin (Moscow, Russian Federation)</td>
</tr>
<tr>
<td>16:05</td>
<td>Treatment programs in COPD</td>
<td>David M. G. Halpin (Exeter, United Kingdom)</td>
</tr>
<tr>
<td>16:15</td>
<td>Rehabilitation programs in COPD</td>
<td>Speaker to be confirmed</td>
</tr>
<tr>
<td>16:25</td>
<td>Discussion and Q &amp; A</td>
<td></td>
</tr>
</tbody>
</table>

### Studio Paris Session 16:50 - 17:50

**Symposium: The future of bronchiectasis management**

**Aims:** To describe the effects of early life, including demographic, inflammatory and genetic factors, on the development of bronchiectasis; to review recent randomised studies and observational data that are leading to improvements in the management of bronchiectasis; to describe current options for the management of Pseudomonas aeruginosa pulmonary infections in patients with bronchiectasis; and to describe possible future treatments for bronchiectasis in adults.

**Disease(s):** Airway diseases, Respiratory infections

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Journalist

**Chairs:** Tobias Welte (Hannover, Germany), Eva Polverino (Barcelona, Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>16:55</td>
<td>Mucus and microbes: why does bronchiectasis develop?</td>
<td>Kathryn Ramsey (Bern, Switzerland)</td>
</tr>
</tbody>
</table>
17:05  State of the art management of bronchiectasis  
Anne O'Donnell (Washington, United States of America)

17:15  Management of chronic airway infection in bronchiectasis  
James D. Chalmers (Dundee (Angus), United Kingdom)

17:25  Where do we go from here? Future directions, endpoints and approaches  
Francesco Blasi (Milan, Italy)

17:35  Discussion and Q & A

Channel 1

Session

16:50 - 18:00

Language session: Spanish/Portuguese programme 2020: Part I  
A joint ERS/ALAT/ASSOBRAFIR/SBPT/SEPAR/SPP session

Aims: To describe the impact of environmental pollution on patients with airway diseases.

Disease(s): Airway diseases, Sleep and breathing disorders

Tag(s): Basic science

Target audience: Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Respiratory physiotherapist, Scientist (basic, translational), Thoracic oncologist, Respiratory therapist, Journalist

Chairs: Carlos Andres Jimenez Ruiz (Madrid, Spain), Chair to be confirmed

16:50  Introduction

16:55  Environmental pollution: a problem in the Iberian Peninsula: view of the Sociedad Española de Neumología y Cirugía Torácica (SEPAR)  
Speaker to be confirmed

17:05  Environmental pollution: a problem in the Iberian Peninsula: view of the Sociedade Portuguesa de Pneumologia (SPP)  
Speaker to be confirmed

17:15  Environmental pollution: a problem in Latin America: view of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)  
Ubiratan Santos (São Paulo (SP), Brazil)

17:25  Environmental pollution: a problem in Latin America: view of the Asociación Latinoamericana de Tórax (ALAT)  
Speaker to be confirmed

17:35  Pollution, air quality and climate change: far beyond wildfire?  
José Rogelio Perez Padilla (México D.F, Mexico)

17:50  Discussion and Q & A

Studio Madrid

Session

16:50 - 17:50

State of the art session: Respiratory critical care

Diagnostic strategies in acute respiratory failure in the ICU

Aims: To describe the diagnostic approach and differential diagnosis of critically ill patients with acute respiratory failure; and to describe the indications and contraindications for invasive diagnostic techniques in these patients.

Disease(s): Interstitial lung diseases, Respiratory critical care, Respiratory infections

Tag(s): Clinical

Target audience: Adult pulmonologist/Clinician, Nurse, Respiratory critical care physician, Patient, Physiologist, Radiologist, Scientist (basic, translational), Respiratory therapist

Chairs: Anita Simonds (London, United Kingdom), Thierry Troosters (Leuven, Belgium)

16:50  Introduction

16:55  The role of computed tomography scanning in the differential diagnosis of acute respiratory failure in ventilated patients

17:05  New molecular diagnostic techniques using bronchoalveolar lavage (BAL) fluid to facilitate the differential diagnosis of acute respiratory failure in intensive care unit patients
17:15  Role of BAL / lung biopsy in the diagnosis of acute respiratory failure in intensive care unit patients  
Venerino Poletti (Forlì, Italy)

17:25  The future of pulmonary diagnostics in intensive care unit patients  
Lieuwe D.J. Bos (Amsterdam, Netherlands)

17:35  Discussion and Q & A

---

**Symposium Madrid**  
**Session**  18:00 - 19:00  
**Symposium: Managing frailty in patients with acute or chronic lung disorders**

**Aims:** To define frailty and its association with various chronic and acute lung disease; to determine the biology underlying frailty in humans and animals; to describe a clear rationale for early mobilisation/rehabilitation in frail patients; and to evaluate rehabilitative interventions to reverse frailty.

**Disease(s):** Airway diseases

**Method(s):** Physiology  Pulmonary rehabilitation  Respiratory intensive care

**Tag(s):** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, General practitioner, Medical Student, Medical Technical Assistant, Nurse, Patient, Physician in Pulmonary Training, Physiologist, Respiratory critical care physician, Respiratory physiotherapist, Journalist, Thoracic surgeon

**Chairs:** Anita Simonds (London, United Kingdom), Thierry Troosters (Leuven, Belgium)

18:00  Introduction

18:05  **Diagnosing management and measures of frailty**  
Speaker to be confirmed

18:14  The biology of frailty

18:23  **Frailty during and after hospitalisation**  
Margaret Herridge (Toronto (ON), Canada)

18:32  **Frailty in chronic lung disorders**  
Lies Lahousse (Ghent, Belgium)

18:41  **Rehabilitative interventions to reverse frailty**  
Matthew Maddocks (London, United Kingdom)

18:50  Discussion and Q & A

---

**Symposium Milan**  
**Session**  18:00 - 19:00  
**Symposium: E-cigarette or Vaping, product use Associated Lung Injury (EVALI)**

**Aims:** To describe the clinical presentation and radiological findings associated with EVALI; to outline the management and outcome of cases with EVALI; to characterize the pathological findings associated with EVALI; to illustrate different heat-not-burn products, their differences and similarities; to estimate the effect of e-cigarettes as a smoking cessation aid; to debate the benefits and drawbacks of e-cigarette strategy as a smoking cessation aid.

**Disease(s):** Airway diseases  Respiratory critical care  Respiratory infections

**Tag:** Clinical

**Target audience:** Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Respiratory critical care physician, Pathologist, Respiratory physiotherapist, Respiratory therapist

**Chairs:** Jørgen Vestbo (Manchester (Greater Manchester), United Kingdom), Sofia Belo Ravara (Covilhã, Portugal)

18:00  Introduction

18:05  **Heated tobacco products - differences and uncertainties**  
Reto Auer (Bern, Switzerland)

18:15  **E-cigarettes and smoking cessation: the evidence or the non-evidence**  
Charlotta Pisinger (Frederiksberg, Denmark)

18:25  **Clinical aspects of lung injury associated with e-cigarettes or vaping**  
Speaker to be confirmed
Lungs on fire: Lung cancer?

Aims: To describe real-life clinical cases during the innovative interactive session, including the presentation of cases that have various levels of difficulty and often necessitate a differential diagnosis. This session will be led by a discussant, who will present the cases to a panel of experts and the audience. The discussant will encourage discussion among the panel of experts, who are encountering these cases for the first time. To further determine diagnostic and therapeutic options for these patients, the discussant will also invite audience participation in the reflexion and discussion of these cases.

Disease(s): Thoracic oncology, Respiratory infections

Tag(s): Clinical

Target audience: Thoracic oncologist, Thoracic surgeon, Respiratory critical care physician, Clinical researcher, General practitioner, Adult pulmonologist/Clinician, Paediatrician, Radiologist, Nurse, Pathologist

Chairs: Joanna Chorostowska-Wynimko (Warsaw, Poland), Otto Chris Burghuber (Wien, Austria), Gilbert Massard (Esch Sur Alzette, Luxembourg)

Discussants: Sam Janes (London, United Kingdom)

18:00 Introduction and presentation by the session facilitator
Sam Janes (London, United Kingdom)

18:04 Case 1

18:14 Discussion and Q & A

18:18 Case 2

18:28 Discussion and Q & A

18:32 Case 3

18:42 Discussion and Q & A

18:46 Case 4

18:56 Discussion and Q & A

Language session: Spanish/Portuguese programme 2020: Part II
A joint ERS/ALAT/ASSOBRAFIR/SBPT/SEPAR/SPP session

Aims: To describe the impact of environmental pollution on patients with airway diseases.

Disease(s): Airway diseases, Sleep and breathing disorders

Tag(s): Basic science

Chairs: José Rogelio Perez Padilla (México D.F, Mexico), Jocimar Avelar Martins (Ponte Nova (MG), Brazil)

18:10 Introduction

18:15 Household pollution and obstructive diseases: asthma and COPD
Jose Miguel Chatkin (Porto Alegre (RS), Brazil)

18:25 Household pollution and lung cancer: beyond tobacco
Speaker to be confirmed

18:35 Physical activity in polluted areas
Fabio Pitta (Londrina, Brazil)

18:45 Discussion and Q & A
INDUSTRY SPONSORED SESSIONS

DISCLAIMER: THE PRACTICAL WORKSHOPS, EVENING SYMPOSIA, EVENING MINI-SYMPOSIA, EVENING EXPERT FORUM SESSIONS AND EARLY MORNING SYMPOSIA ARE ORGANISED BY INDUSTRY. YOU CANNOT CLAIM CME CREDITS FOR ATTENDING THESE SESSIONS.
# CHAIR AND COORDINATOR INDEX

Name, Session number

<table>
<thead>
<tr>
<th>A</th>
<th>MORAI S. A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALIVERTI A.</td>
<td></td>
</tr>
<tr>
<td>ANNEMA J.</td>
<td></td>
</tr>
<tr>
<td>ANTONIOU K.</td>
<td></td>
</tr>
<tr>
<td>AVELAR MARTINS J.</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
</tr>
<tr>
<td>BEEH K.</td>
<td></td>
</tr>
<tr>
<td>BELEVSKIIY A.</td>
<td></td>
</tr>
<tr>
<td>BELO RAVARA S.</td>
<td></td>
</tr>
<tr>
<td>BLUM T.</td>
<td></td>
</tr>
<tr>
<td>BOTHAMLEY G.</td>
<td></td>
</tr>
<tr>
<td>BRIGHTLING C.</td>
<td></td>
</tr>
<tr>
<td>BURGHEBER O.</td>
<td></td>
</tr>
<tr>
<td>BUSH A.</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td></td>
</tr>
<tr>
<td>CHEN R.</td>
<td></td>
</tr>
<tr>
<td>CHOROSTOWSKA-WYNIMKO J.</td>
<td></td>
</tr>
<tr>
<td>CHUCHALIN A.</td>
<td></td>
</tr>
<tr>
<td>CLINI E.</td>
<td></td>
</tr>
<tr>
<td>COHEN TODD M.</td>
<td></td>
</tr>
<tr>
<td>COSTELLO R.</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
</tr>
<tr>
<td>DE WEVER W.</td>
<td></td>
</tr>
<tr>
<td>DELCROIX M.</td>
<td></td>
</tr>
<tr>
<td>DINH-XUAN A.</td>
<td></td>
</tr>
<tr>
<td>DUIVERMAN M.</td>
<td></td>
</tr>
<tr>
<td>E</td>
<td></td>
</tr>
<tr>
<td>EBER E.</td>
<td></td>
</tr>
<tr>
<td>ELIA S.</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td></td>
</tr>
<tr>
<td>GAGA M.</td>
<td></td>
</tr>
<tr>
<td>GATTA M.</td>
<td></td>
</tr>
<tr>
<td>GEISE T.</td>
<td></td>
</tr>
<tr>
<td>GOSENS R.</td>
<td></td>
</tr>
<tr>
<td>GREENE C.</td>
<td></td>
</tr>
<tr>
<td>GRIEG J.</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td></td>
</tr>
<tr>
<td>HALPIN D.</td>
<td></td>
</tr>
<tr>
<td>HARDAVELLA G.</td>
<td></td>
</tr>
<tr>
<td>HARTL S.</td>
<td></td>
</tr>
<tr>
<td>HEUNKS L.</td>
<td></td>
</tr>
<tr>
<td>HUMBERT M.</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td></td>
</tr>
<tr>
<td>IDZO M.</td>
<td></td>
</tr>
<tr>
<td>J</td>
<td></td>
</tr>
<tr>
<td>JANSON C.</td>
<td></td>
</tr>
<tr>
<td>JIMENEZ RUIZ C.</td>
<td></td>
</tr>
<tr>
<td>JUTEL M.</td>
<td></td>
</tr>
<tr>
<td>K</td>
<td></td>
</tr>
<tr>
<td>KOCKS J.</td>
<td></td>
</tr>
<tr>
<td>KREUTER M.</td>
<td></td>
</tr>
<tr>
<td>L</td>
<td></td>
</tr>
<tr>
<td>LANGER D.</td>
<td></td>
</tr>
<tr>
<td>LAVENEZIANA P.</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>MAITRE B.</td>
<td></td>
</tr>
<tr>
<td>MASSARD G.</td>
<td></td>
</tr>
<tr>
<td>MEINERS S.</td>
<td></td>
</tr>
<tr>
<td>MELONI F.</td>
<td></td>
</tr>
<tr>
<td>MIDULLA F.</td>
<td></td>
</tr>
<tr>
<td>MOLINA MOLINA M.</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>NIELSEN K.</td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>PEPKE-ZABA J.</td>
<td></td>
</tr>
<tr>
<td>PEREZ PADILLA J.</td>
<td></td>
</tr>
<tr>
<td>PINENBURG M.</td>
<td></td>
</tr>
<tr>
<td>PINNOCK H.</td>
<td></td>
</tr>
<tr>
<td>POLETTI V.</td>
<td></td>
</tr>
<tr>
<td>POLVERINO E.</td>
<td></td>
</tr>
<tr>
<td>PROESMANS M.</td>
<td></td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>QU J.</td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>RAHERISON-SEMJEN C.</td>
<td></td>
</tr>
<tr>
<td>RIEMEKASTEN G.</td>
<td></td>
</tr>
<tr>
<td>ROBALO CORDEIRO C.</td>
<td></td>
</tr>
<tr>
<td>ROHDE G.</td>
<td></td>
</tr>
<tr>
<td>ROSENKRANZ S.</td>
<td></td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>SANDELOWSKY H.</td>
<td></td>
</tr>
<tr>
<td>SCHENK P.</td>
<td></td>
</tr>
<tr>
<td>SCHUHMHANN M.</td>
<td></td>
</tr>
<tr>
<td>SCHULTZ M.</td>
<td></td>
</tr>
<tr>
<td>SIMONDS A.</td>
<td></td>
</tr>
<tr>
<td>SITBON O.</td>
<td></td>
</tr>
<tr>
<td>SPANEVELLO A.</td>
<td></td>
</tr>
<tr>
<td>SPRUIT M.</td>
<td></td>
</tr>
<tr>
<td>STOLZ D.</td>
<td></td>
</tr>
<tr>
<td>SUPPLI ULRUK C.</td>
<td></td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>TAMM M.</td>
<td></td>
</tr>
<tr>
<td>TAN TZE L.</td>
<td></td>
</tr>
<tr>
<td>TROOSTERS T.</td>
<td></td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>UBAGS N.</td>
<td></td>
</tr>
<tr>
<td>ULLER L.</td>
<td></td>
</tr>
<tr>
<td>USMANI O.</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>VAN MEERBEEK J.</td>
<td></td>
</tr>
<tr>
<td>VESTBO J.</td>
<td></td>
</tr>
<tr>
<td>VOGIATZIS I.</td>
<td></td>
</tr>
<tr>
<td>VONK NOORDEGRAAF A.</td>
<td></td>
</tr>
<tr>
<td>W</td>
<td></td>
</tr>
<tr>
<td>WEDZICHA W.</td>
<td></td>
</tr>
<tr>
<td>WELTE T.</td>
<td></td>
</tr>
<tr>
<td>WIJSENBEEK M.</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>YORGANCIOLU A.</td>
<td></td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
<tr>
<td>ZACHARASIEWICZ A.</td>
<td></td>
</tr>
</tbody>
</table>

25.06.2020
## DISCUSSANT INDEX

Name, Session number

<p>| C     | CHAUDHURI N.   |
| H     | HAMMER J.     |
| J     | JANES S.      |
| P     | PEPKE-ZABA J. |
| S     | SINGH D.      |
| T     | TAMM M.       |
| T     | TORRES A.     |</p>
<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>WATERER G.</td>
</tr>
<tr>
<td>WELLS A.</td>
</tr>
<tr>
<td>WELTE T.</td>
</tr>
<tr>
<td>WIJSENBEEK M.</td>
</tr>
<tr>
<td>WILSON M.</td>
</tr>
<tr>
<td>WINDISCH W.</td>
</tr>
<tr>
<td>WINTHROP K.</td>
</tr>
<tr>
<td>WOLTERS P.</td>
</tr>
<tr>
<td>WUYTS W.</td>
</tr>
<tr>
<td>X</td>
</tr>
<tr>
<td>XIAO Y.</td>
</tr>
<tr>
<td>Y</td>
</tr>
<tr>
<td>YORGANCIOLU A.</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>ZHAI Z.</td>
</tr>
<tr>
<td>ZHONG N.</td>
</tr>
</tbody>
</table>